

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number  
**WO 01/97850 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 45/06**

(21) International Application Number: PCT/EP01/06976

(22) International Filing Date: 20 June 2001 (20.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
00250194.8 23 June 2000 (23.06.2000) EP  
00250214.4 28 June 2000 (28.06.2000) EP

(71) Applicant: **SCHERING AKTIENGESELLSCHAFT**  
[DE/DE]; Müllerstrasse 178, 13353 Berlin (DE).

(71) Applicants and

(72) Inventors: **SIEMEISTER, Gerhard** [DE/DE]; Reimerswalder Steig 26, 13503 Berlin (DE). **HABEREY, Martin** [DE/DE]; Steinstr. 1, 12169 Berlin (DE). **THIERAUCH, Karl-Heinz** [DE/DE]; Hochwildpfad 45, 14169 Berlin (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

**BEST AVAILABLE COPY**



**WO 01/97850 A2**

(54) Title: COMBINATIONS AND COMPOSITIONS WHICH INTERFERE WITH VEGF/VEGF AND ANGIOPOIETIN/TIE RECEPTOR FUNCTION AND THEIR USE (II)

(57) Abstract: The present invention describes the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

**Combinations and compositions which interfere with VEGF/ VEGF and  
angiopoietin/ Tie receptor function and their use (II)**

5 The present invention provides the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

10

Protein ligands and receptor tyrosine kinases that specifically regulate endothelial cell function are substantially involved in physiological as well as in disease-related angiogenesis. These ligand/receptor systems include the Vascular Endothelial Growth Factor (VEGF) and the Angiopoietin (Ang) families, and their  
15 receptors, the VEGF receptor family and the tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family. The members of the two families of receptor tyrosine kinases are expressed primarily on endothelial cells. The VEGF receptor family includes Flt1 (VEGF-R1), Flk1/KDR (VEGF-R2), and Flt4 (VEGF-R3). These receptors are recognized by members of  
20 the VEGF-related growth factors in that the ligands of Flt1 are VEGF and placenta growth factor (PlGF), whereas Flk1/KDR binds VEGF, VEGF-C and VEGF-D, and the ligands of Flt4 are VEGF-C and VEGF-D (Nicosia, Am. J. Pathol. 153, 11-16, 1998). The second family of endothelial cell specific receptor tyrosine kinases is represented by Tie1 and Tie2 (also known as Tek). Whereas Tie1 remains an  
25 orphan receptor, three secreted glycoprotein ligands of Tie2, Ang1, Ang2, and Ang3/Ang4 have been discovered (Davis et al., Cell 87, 1161-1169, 1996; Maisonpierre et al., Science 277, 55-60, 1997; Valenzuela et al, Proc. Natl. Acad. Sci. USA 96, 1904-1909, 1999; patents: US 5,521,073; US 5,650,490; US 5,814,464).

30

The pivotal role of VEGF and of its receptors during vascular development was exemplified in studies on targeted gene inactivation. Even the heterozygous disruption of the VEGF gene resulted in fatal deficiencies in vascularization (Carmeliet et al., Nature 380, 435-439, 1996; Ferrara et al., Nature 380, 439-442,

1996). Mice carrying homozygous disruptions in either Flt1 or Flk1/KDR gene die in mid-gestation of acute vascular defects. However, the phenotypes are distinct in that Flk1/KDR knock-out mice lack both endothelial cells and a developing hematopoietic system (Shalaby et al. Nature 376, 62-66, 1995), whereas Flt1  
5 deficient mice have normal hematopoietic progenitors and endothelial cells, which fail to assemble into functional vessels (Fong et al., 376, 66-70, 1995). Disruption of the Flt4 gene, whose extensive embryonic expression becomes restricted to lymphatic vessels in adults, revealed an essential role of Flt4 for the remodeling and maturation of the primary vascular networks into larger blood vessels during  
10 early development of the cardiovascular system (Dumont et al., Science 282, 946-949, 1998). Consistent with the lymphatic expression of Flt4 in adults overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeltsch et al., Science 276, 1423-1425, 1997). Moreover, VEGF-C was reported to induce  
15 neovascularization in mouse cornea and chicken embryo chorioallantoic membrane models of angiogenesis (Cao et al., Proc. Natl. Acad. Sci. USA 95, 14389-14394, 1998).

The second class of endothelial cell specific receptor tyrosine kinases has also  
20 been found to be critically involved in the formation and integrity of vasculature. Mice deficient in Tie1 die of edema and hemorrhage resulting from poor structural integrity of endothelial cells of the microvasculature (Sato et al., Nature 376, 70-74, 1995; Rodewald & Sato, Oncogene 12, 397-404, 1996). The Tie2 knock-out phenotype is characterized by immature vessels lacking branching networks and  
25 lacking periendothelial support cells (Sato et al., Nature 376, 70-74, 1995; Dumont et al., Genes Dev. 8, 1897-1909, 1994). Targeted inactivation of the Tie2 ligand Ang1, as well as overexpression of Ang2, an inhibitory ligand, resulted in phenotypes similar to the Tie2 knock out (Maisonpierre et al., Science 277, 55-60, 1997; Suri et al., cell 87, 1171-1180). Conversely, increased vascularization was  
30 observed upon transgenic overexpression of Ang1 (Suri et al., Science 282, 468-471, 1998; Thurston et al., Science 286, 2511-2514, 1999).

The results from angiogenic growth factor expression studies in corpus luteum development (Maisonpierre et al., Science 277, 55-60, 1997; Goede et al. Lab.

Invest. 78, 1385-1394, 1998), studies on blood vessel maturation in the retina (Alon et al., Nature Med. 1, 1024-1028, 1995; Benjamin et al, Development 125, 1591-1598, 1998), and gene targeting and transgenic experiments on Tie2, Ang1, and Ang2, suggest a fundamental role of the Angiopoietin/Tie receptor system in mediating interactions between endothelial cells and surrounding pericytes or smooth muscle cells. Ang1, which is expressed by the periendothelial cells and seems to be expressed constitutively in the adult, is thought to stabilize existing mature vessels. Ang2, the natural antagonist of Ang1 which is expressed by endothelial cells at sites of vessel sprouting, seems to mediate loosening of endothelial-peri endothelial cell contacts to allow vascular remodeling and sprouting in cooperation with angiogenesis initiators such as VEGF, or vessel regression in the absence of VEGF (Hanahan, Science 277, 48-50, 1997).

In pathological settings associated with aberrant neovascularization elevated expression of angiogenic growth factors and of their receptors has been observed. Most solid tumors express high levels of VEGF and the VEGF receptors appear predominantly in endothelial cells of vessels surrounding or penetrating the malignant tissue (Plate et al., Cancer Res. 53, 5822-5827, 1993). Interference with the VEGF/VEGF receptor system by means of VEGF-neutralizing antibodies (Kim et al., Nature 362, 841-844, 1993), retroviral expression of dominant negative VEGF receptor variants (Millauer et al., Nature 367, 576-579, 1994), recombinant VEGF-neutralizing receptor variants (Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998), or small molecule inhibitors of VEGF receptor tyrosine kinase (Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000), or targeting cytotoxic agents via the VEGF/VEGF receptor system (Arora et al., Cancer Res. 59, 183-188, 1999; EP 0696456A2) resulted in reduced tumor growth and tumor vascularization. However, although many tumors were inhibited by interference with the VEGF/VEGF receptor system, others were unaffected (Millauer et al., Cancer Res. 56, 1615-1620, 1996). Human tumors as well as experimental tumor xenografts contain a large number of immature blood vessels that have not yet recruited periendothelial cells. The fraction of immature vessels is in the range of 40% in slow growing prostate cancer and 90% in fast growing glioblastoma. A selective obliteration of immature tumor vessels was observed upon withdrawal of

- VEGF by means of downregulation of VEGF transgene expression in a C6 glioblastoma xenograft model. This result is in accordance with a function of VEGF as endothelial cell survival factor. Similarly, in human prostate cancer shutting off VEGF expression as a consequence of androgen-ablation therapy led to selective apoptotic death of endothelial cells in vessels lacking periendothelial cell coverage. In contrast, the fraction of vessels which resisted VEGF withdrawal showed periendothelial cell coverage (Benjamin et al., J. Clin. Invest. 103, 159-165, 1999).
- 10 The observation of elevated expression of Tie receptors in the endothelium of metastatic melanomas (Kaipainen et al., Cancer Res. 54, 6571-6577, 1994), in breast carcinomas (Salvén et al., Br. J. Cancer 74, 69-72, 1996), and in tumor xenografts grown in the presence of dominant-negative VEGF receptors (Millauer et al., Cancer Res. 56, 1615-1620, 1996), as well as elevated expression of Flt4
- 15 receptors in the endothelium of lymphatic vessels surrounding lymphomas and breast carcinomas (Jussila et al., Cancer Res. 58, 1599-1604, 1998), and of VEGF-C in various human tumor samples (Salvén et al., Am. J. Pathol. 153, 103-108, 1998), suggested these endothelium-specific growth factors and receptors as candidate alternative pathways driving tumor neovascularization. The high
- 20 upregulation of Ang2 expression already in early tumors has been interpreted in terms of a host defense mechanism against initial cooption of existing blood vessels by the developing tumor. In the absence of VEGF, the coopted vessels undergo regression leading to necrosis within the center of the tumor. Contrarily, hypoxic upregulation of VEGF expression in cooperation with elevated Ang2
- 25 expression rescues and supports tumor vascularization and tumor growth at the tumor margin (Holash et al., Science 284, 1994-1998, 1999; Holash et al., Oncogene 18, 5356-5362, 1999).
- Interference with Tie2 receptor function by means of Angiopoietin-neutralizing
- 30 Tie2 variants consisting of the extracellular ligand-binding domain has been shown to result in inhibition of growth and vascularization of experimental tumors (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al. Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Comparing the effects of interference with the endothelium-specific receptor

tyrosine kinase pathways by means of paracrine expression of the respective extracellular receptor domains on the same cellular background demonstrated inhibition of tumor growth upon blockade of the VEGF receptor system and of the Tie2 receptor system, respectively (Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

It is known that the inhibition of the VEGF/VEGR receptor system by various methods resulted only in slowing down growth of most experimental tumors (Millauer et al., Nature 367, 576-579, 1994; Kim et al., Nature 362, 841-844, 1993; Millauer et al., Cancer Res. 56, 1615-1620, 1996; Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998; Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Even by escalation of therapeutic doses a plateau level of therapeutic efficacy was achieved (Kim et al., Nature 362, 841-844, 1993; Wood et al. Cancer Res. 60, 2178-2189, 2000). Similar results were observed upon interference with the Angiopoietin/Tie2 receptor system (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al., Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

However, there is a high demand for methods that enhance the therapeutic efficacy of anti-angiogenous compounds.

Searching for methods that enhance the therapeutic efficacy of anti-angiogenic compounds, superior anti-tumor effects were observed unexpectedly upon combination of inhibition of VEGF/VEGF receptor systems and interference with biological function of Angiopoietin/Tie receptor systems. The mode of action underlying the superior effects observed may be that interference biological function of Angiopoietin/Tie receptor systems destabilizes endothelial cell-peri-endothelial cell interaction of existing mature tumor vessels and thereby sensitizes the endothelium to compounds directed against VEGF/VEGF receptor systems.

Based on this unexpected finding the present invention provides the combination of functional interference with VEGF/VEGF receptor systems and with

Angiopoietin/Tie receptor systems for inhibition of vascularization and of tumor growth.

The pharmaceutical composition consists of two components: compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or  
5 consists of cytotoxic agents which are targeted to the endothelium via recognition of VEGF/VEGF receptor systems. Compound II interferes with the biological function of one or several of Angiopoietin/Tie receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of Angiopoietin/Tie receptor systems. Alternatively, compound I inhibits the biological  
10 activity of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems and compound II consists of cytotoxic agents which are targeted to the endothelium via recognition of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems. Targeting or modulation of the biological activities of VEGF/VEGF receptor  
15 systems and of Angiopoietin/Tie receptor systems can be performed by

- (a) compounds which inhibit receptor tyrosine kinase activity,
- (b) compounds which inhibit ligand binding to receptors,
- (c) compounds which inhibit activation of intracellular signal pathways of the  
20 receptors,
- (d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- (e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents  
25 or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- (f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

30

A compound comprised by compositions of the present invention can be a small molecular weight substance, an oligonucleotide, an oligopeptide, a recombinant protein, an antibody, or conjugates or fusionproteins thereof. An example of an inhibitor is a small molecular weight molecule which inactivates a receptor tyrosine

kinase by binding to and occupying the catalytic site such that the biological activity of the receptor is decreased. Kinase inhibitors are known in the art (Sugen: SU5416, SU6668; Fong et al. (1999), *Cancer Res.* 59, 99-106; Vajkoczy et al., *Proc. Am. Associ. Cancer Res. San Francisco* (2000), Abstract ID 3612; Zeneca: ZD4190, ZD6474; Wedge et al. (2000), *Cancer Res.* 60, 970-975; Parke-Davis PD0173073, PD0173074; Johnson et al., *Proc. Am. Associ. Cancer Res., San Francisco* (2000), Abstract ID 3614; Dimitroff et al. (1999), *Invest. New Drugs* 17, 121-135). An example of an antagonist is a recombinant protein or an antibody which binds to a ligand such that activation of the receptor by the ligand is prevented. Another example of an antagonist is an antibody which binds to the receptor such that activation of the receptor is prevented. An example of an expression modulator is an antisense RNA or ribozyme which controls expression of a ligand or a receptor. An example of a targeted cytotoxic agent is a fusion protein of a ligand with a bacterial or plant toxin such as *Pseudomonas* exotoxin A, Diphtheria toxin, or Ricin A. An example of a targeted coagulation-inducing agent is a conjugate of a single chain antibody and tissue factor. Ligand-binding inhibitors such as neutralizing antibodies which are known in the art are described by Genentech (rhuMAbVEGF) and by Presta et al. (1997), *Cancer Res.* 57, 4593-4599. Ligand-binding receptor domains are described by Kendall & Thomas (1993), *Proc. Natl. Acad. Sci., U.S.A.* 90, 10705-10709; by Goldman et al. (1998) *Proc. Natl. Acad. Sci., U.S.A.* 95, 8795-8800 and by Lin et al. (1997), *J. Clin. Invest.* 100, 2072-2078. Further, dominant negative receptors have been described by Millauer et al. (1994), *Nature* 367, 567-579.

Receptor blocking antibodies have been described by Imclone (c-p1C11, US 5,874,542). Further known are antagonistic ligand mutants (Siemeister et al. (1998), *Proc. Natl. Acad. Sci., U.S.A.* 95, 4625-4629). High affinity ligand- or receptor binding oligo nucleotides have been described by NeXstar (NX-244) and Drolet et al. (1996), *Nat. Biotech* 14, 1021-1025. Further, small molecules and peptides have been described.


Expression regulators have been described as anti-sense oligo nucleotides and as ribozymes (RPI, Angiozyme™, see RPI Homepage).



Examples for delivery-/Targeting-Systems have been described as ligand/  
 antibody-toxin-fusion-proteins or conjugates (Arora et al. (1999), Cancer Res. 59,  
 183-188 and Olson et al. (1997), Int. J. Cancer 73, 865-870), as endothel cell  
 targeting of liposomes (Spragg et al. (1997), Prog. Natl. Acad. Sci. U.S.A94, 8795-  
 5 8800, and as endothel cell targeting plus coagulation-induction (Ran et al., (1998),  
 Cancer Res. 58, 4646-4653).

10 Small molecules which inhibit the receptor tyrosine kinase activity are for example  
 molecules of general formula I

15



20

in which

r has the meaning of 0 to 2,


n has the meaning of 0 to 2;

25

R<sub>3</sub> und R<sub>4</sub> a) each independently from each other have the meaning  
 of lower alkyl,

9

b) together form a bridge of general partial formula II;




5

m

wherein the binding is via the two terminal C- atoms, and  
has the meaning of 0 to 4; or

c) together form a bridge of partial formula III

10



15

wherein one or two of the ring members  $T_1, T_2, T_3, T_4$  has the  
meaning of nitrogen, and each others have the meaning of  
CH, and the bining is via the atoms  $T_1$  and  $T_4$ ;

G

20

has the meaning of  $C_1 - C_6$  - alkyl,  $C_2 - C_6$  - alkylene or  
 $C_2 - C_6$  - alkenylene; or  $C_2 - C_6$  - alkylene or  $C_3 - C_6$  - alkeny-  
lene, which are substituted with acyloxy or hydroxy;  $-CH_2-O-$ ,  
 $-CH_2-S-$ ,  $-CH_2-NH-$ ,  $-CH_2-O-CH_2-$ ,  $-CH_2-S-CH_2-$ ,  
 $-CH_2-NH-CH_2$ , oxa ( $-O-$ ), thia ( $-S-$ ) or imino ( $-NH-$ ),

A, B, D, E and T

25

independently from each other have the meaning of N or CH ,  
with the provisio that not more than three of these  
Substituents have the meaning of N,

- Q has the meaning of lower alkyl, lower alkyloxy or halogene,  
R<sub>1</sub> and R<sub>2</sub> independently from each other have the meaning of H or  
lower alkyl,
- X has the meaning of imino, oxa or thia;
- 5 Y has the meaning of hydrogene, unsubstituted or substituted  
aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and
- Z has the meaning of amino, mono- or disubstituted amino,  
halogen, alkyl, substituted alkyl, hydroxy, etherificated or  
esterificated hydroxy, nitro, cyano, carboxy, esterificated  
10 carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted  
carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio,  
phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl,  
phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl,  
phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if  
15 more than one rest Z is present ( $m \geq 2$ ), the substituents Z are  
equal or different from each other, and wherein the bonds  
marked with an arrow are single or double bonds; or an N-  
oxide of said compound, wherein one ore more N-atoms carry  
an oxygene atom, or a salt thereof.

20

A preferred salt is the salt of an organic acid, especially a succinate.


These compounds can preferentially be used as compound I or II in the inventive  
pharmaceutical composition.

25

Compounds which stop a tyrosin phosphorylation, or the persistent angiogenese,  
respectively, which results in a prevention of tumor growth and tumor spread, are  
for example

anthranyl acid derivatives of general formula IV

30



in which

A

has the meaning of group  $=NR^2$ ,

5


W

has the meaning of oxygen, sulfur, two hydrogen atoms or the group  $=NR^8$ ,

Z

has the meaning of the group  $=NR^{10}$  or  $=N-$ ,  $-N(R^{10})-$ ,  $(CH_2)_q-$ , branched or unbranched  $C_{1-6}$ -Alkyl or is the group


10



15

or A, Z and  $R^1$  together form the group

20



m, n and o

q

R<sub>a</sub>, R<sub>b</sub>, R<sub>c</sub>, R<sub>d</sub>, R<sub>e</sub>, R<sub>f</sub>

has the meaning of 0 – 3,

has the meaning of 1 – 6,

independently from each other have the meaning of hydrogen, C<sub>1-4</sub> alkyl or the group =NR<sup>10</sup>, and/or R<sub>a</sub> and/or R<sub>b</sub> together with R<sub>c</sub> and/or R<sub>d</sub> or R<sub>c</sub> together with R<sub>e</sub> and/or R<sub>f</sub> form a bound, or up to two of the groups R<sub>a</sub>-R<sub>f</sub> form a bridge with each up to 3 C-atoms with R<sup>1</sup> or R<sup>2</sup>,

has the meaning of group =NR<sup>9</sup> or =N-has the meaning of group -(CH<sub>2</sub>)<sub>p</sub>,

has the meaning of integer 1-4,

has the meaning of unsubstituted or optionally substituted with one or more of halogene, C<sub>1-6</sub>-alkyl, or C<sub>1-6</sub>-alkyl or C<sub>1-6</sub>-alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,

R<sup>2</sup>has the meaning of hydrogen or C<sub>1-6</sub>-alkyl, or

form a bridge with up to 3 ring atoms with R<sub>a</sub>-R<sub>f</sub> together with Z or R<sub>1</sub>,

R<sup>3</sup>


has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of für halogen, C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-alkoxy or hydroxy,

R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup>

independently from each other have the meaning of hydrogen, halogen or C<sub>1-6</sub>-alkoxy, C<sub>1-6</sub>-alkyl or

13


C<sub>1-6</sub>-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogen, or R<sup>5</sup> and R<sup>6</sup> together form the group



- 5            R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup>            independently from each other have the meaning of hydrogen or C<sub>1-6</sub>-alkyl, as well as their isomers and salts.

10        These compounds can also preferentially be used as compound I or II in the inventive pharmaceutical composition.

More preferentially compounds of general formula V





15

in which


R<sup>1</sup>            has the meaning of group

20






in which  $R^5$  is chloro, bromo or the group  $-OCH_3$ ,



in which  $R^7$  is  $-CH_3$  or chloro,



in which  $R^8$  is  $-CH_3$ , fluoro,  
chloro or  $-CF_3$


in which  $R^4$  is fluoro,  
chloro, bromo,  $-CF_3$ ,  
 $-N=C$ ,  $-CH_3$ ,  $-OCF_3$  or  
 $-CH_2OH$

in which  $R^6$  is  
 $-CH_3$  or chloro

5

$R^2$

has the meaning of pyridyl or the group



10

and

$R^3$

has the meaning of hydrogen or fluoro, as well as their  
isomers and salts can be used as compound I or II in the inventive pharmaceutical  
composition.

These compounds have the same properties as already mentioned above under  
compound IV and can be used for the treatment of angiogeneous diseases.  
Compositions comprise compounds of general formulars I, IV and V, alone or in  
combination.

The above mentioned compounds are also claimed matter within the inventive  
combinations.

20

A further example for ligand binding inhibitors are peptides and DNA sequences  
coding for such peptides, which are used for the treatment of angiogeneous  
diseases. Such peptides and DNA sequences are disclosed in Seq. ID No. 1 to 59  
of the sequence protocoll. It has been shown that Seq. ID Nos. 34 and 34a are of  
main interest.

25

Claimed matter of the instant invention are therefor pharmaceutical compositions



- 5 a) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,
- 10 b) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,
- 15 c) comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/ Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium,
- 20 d) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,
- 25 e) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,
- 30 f) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems,
- g) comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems and

h) comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

5

For a sequential therapeutical application the inventive pharmaceutical compositions can be applied simultaneously or separately .

The inventive compositions comprise as compound I or as compound II at least one of

10

- a) compounds which inhibit receptor tyrosine kinase activity,
- b) compounds which inhibit ligand binding to receptors,
- c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- 15 d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of
- 20 VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

These compositions are also claimed matter of the present invention.

25

Also claimed matter of the present invention are pharmaceutical compositions which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

30

Of most value are pharmaceutical compositions, which comprise as compound I and/ or II Seq. ID Nos. 34a und pharmaceutical compositions according to claims which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

Further preferred matter of the present invention are pharmaceutical compositions, which comprise as compound I and/ or II at least one small molecule of general formula I, general formula IV and/ or general formula V.

- 5 The most preferred compound which can be used as compound I or II in the inventive composition is (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate.
- Therefore, claimed matter of the present invention are also pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II, and most preferred pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35; pharmaceutical compositions, which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

- The small molecule compounds, proteins and DNA's expressing proteins, as mentioned above can be used as medicament alone, or in form of formulations for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis and damage of nerve tissues.

The treatment of the damaged nerve tissues with the inventive combination hinders the rapid formation of scars at the damaged position. Thus, there is no

scar formation before the axons communicate with each other. Therefore a reconstruction of the nerve bindings is much more easier.

Further, the inventive combinations can be used for suppression of the ascites  
5 formation in patients. It is also possible to suppress VEGF oedemas.

For the use of the inventive combinations as medicament the compounds will be formulated as pharmaceutical composition. Said formulation comprises beside the active compound or compounds acceptable pharmaceutically, organically or inorganically inert carriers, such as water, gelatine, gum arabic, lactose, starch,  
10 magnesium stearate, talcum, plant oils, polyalkylene glycols, etc. Said pharmaceutical preparations can be applied in solid form, such as tablets, pills, suppositories, capsules, or can be applied in fluid form, such as solutions, suspensions or emulsions.

If necessary, the compositions additionally contain additives, such as  
15 preservatives, stabilizer, detergents or emulgators, salts for alteration of the osmotic pressure and/ or buffer.

These uses are also claimed matter of the instant invention, as well as the formulations of the active compounds

20 For parenteral application especially injectable solutions or suspensions are suitable, especially hydrous solutions of the active compound in polyhydroxyethoxylated castor-oil are suitable.

As carrier also additives can be used, such as salts of the gallic acid or animal or plant phospholipids, as well as mixtures thereof, and liposomes or ingredients  
25 thereof.

For oral application especially suitable are tablets, pills or capsules with talcum and/ or hydrocarbon carriers or binders, such as lactose, maize or potato starch.

The oral application can also be in form of a liquid, such as juice, which optionally contains a sweetener.

30 The dosis of the active compound differs depending on the application of the compound, age and weight of the patient, as well as the form and the progress of the disease.

The daily dosage of the active compound is 0,5-1000 mg, especially 50-200 mg.

The dosis can be applied as single dose or as two or more daily dosis.

These formulations and application forms are also part of the instant invention.

- Combined functional interference with VEGF/VEGF receptor systems and with  
5 Angiopoietin/Tie receptor systems can be performed simultaneously, or in  
sequential order such that the biological response to interference with one  
ligand/receptor system overlaps with the biological response to interference with a  
second ligand/receptor system. Alternatively, combined functional interference  
with VEGF/VEGF receptor systems or with Angiopoietin/Tie receptor systems and  
10 targeting of cytotoxic agents via VEGF/VEGF receptor systems or via  
Angiopoietin/Tie receptor systems can be performed simultaneously, or in  
sequential order such that the biological response to functional interference with a  
ligand/receptor system overlaps in time with targeting of cytotoxic agents.
- 15 The invention is also directed to a substance which functional interferes with both  
VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems, or which  
are targeted via both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor  
systems.
- 20 VEGF/VEGF receptor systems include the ligands VEGF-A, VEGF-B, VEGF-C,  
VEGF-D, PlGF, and the receptor tyrosine kinases VEGF-R1 (Flt1), VEGF-R2  
(KDR/Flk1), VEGF-R3 (Flt4), and their co-receptors (i.e. neuropilin-1).  
Angiopoietin/Tie receptor systems include Ang1, Ang2, Ang3/Ang4, and  
angiopoietin related polypeptides which bind to Tie1 or to Tie2, and the receptor  
25 tyrosine kinases Tie1 and Tie2.

- Pharmaceutical compositions of the present invention can be used for medicinal  
purposes. Such diseases are, for example, cancer, cancer metastasis,  
angiogenesis including retinopathy and psoriasis. Pharmaceutical compositions of  
30 the present invention can be applied orally, parenterally, or via gene therapeutic  
methods.

Therefor the present invention also concerns the use of pharmaceutical  
compositions for the production of a medicament for the treatment of tumors,

cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections  
5 and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

The following examples demonstrate the feasibility of the disclosed invention, without restricting the invention to the disclosed examples.

## 5    **Example 1**

Superior effect on inhibition of tumor growth via combination of inhibition of the VEGF A/VEGF receptor system together with functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention was demonstrated in an A375v human melanoma xenograft model.

10

Human melanoma cell line A375v was stably transfected to overexpress the extracellular ligand-neutralizing domain of human Tie2 receptor tyrosine kinase (sTie2; compound II) (Siemeister et al., Cancer Res. 59, 3185-3191, 1999). For control, A375v cells were stably transfected with the empty expression vector  
15 (A375v/pCEP). Swiss *nu/nu* mice were s.c. injected with  $1 \times 10^6$  transfected A375v/sTie2 or A375v/pCEP tumor cells, respectively. Animals receiving compound I were treated for up to 38 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60,  
20 2178-2189, 2000). Various modes of treatment are described in Table 1. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 1

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 250 mm<sup>2</sup> (mean area) within 24 days (Figure 1) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) or
- 10 separate interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) delayed growth of tumors to a size of approx. 250 mm<sup>2</sup> to 31 days, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of interference with the VEGF/VEGF receptor system by means of the kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen
- 15 succinate (compound I + compound II, treatment group 4) delayed growth of the tumors to a size of approx. 250 mm<sup>2</sup> to 38 days.

This result clearly demonstrates the superior effect of a combination of interference with the VEGF-A/VEGF receptor system and the Angiopoietin/Tie2 receptor system over separate modes of intervention.



**Example 2**

Combination of functional interference with the Angiopoietin/Tie2 receptor system and neutralization of VEGF-A is superior to separate modes of intervention in  
 5 inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated twice weekly over a period of time of 4 weeks with intraperitoneal doses of  
 10 200 µg of the VEGF-A-neutralizing monoclonal antibody (mAb) 4301-42-35 (Schlaeppli et al., J. Cancer Res. Clin. Oncol. 125, 336-342, 1999). Various modes of treatment are described in Table 2. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its  
 15 perpendicular.

Table 2

treatment group	mode of treatment	
	mAb 4301-42-35 (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000  
 20 mm<sup>3</sup> within 28 days (Figure 2) without treatment (group 1). Tumors treated with the VEGF-A-neutralizing mAb 4301-42-35 (compound I, treatment group 2) grew to a volume of approx. 450 mm<sup>3</sup> within 28 days. Interference with

Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm<sup>2</sup>, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and neutralizing of VEGF-A by means of the mAb 4301-42-35 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm<sup>3</sup> within 28 days.

The superior effect of a combination of neutralization of VEGF-A and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

**Example 3**

Combination of functional interference with the Angiopoietin/Tie2 receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

5

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) was expressed in *E. coli* and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm<sup>3</sup> animals receiving compound I were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 3. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

10

15

Table 3

treatment group	mode of treatment	
	scFv-tTF conjugate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm<sup>3</sup> within 28 days (Figure 3) without treatment (group 1). Tumors treated with the coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound I, treatment group 2) grew to a volume of approx. 500 mm<sup>3</sup> within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm<sup>2</sup>, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 300 mm<sup>3</sup> within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown. Similar effects can be expected upon targeting of cytotoxic agents to VEGF/VEGF receptor systems.

**Example 4**

Combination of functional interference with the VEGF/VEGF receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of a single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) which was expressed in *E. coli* and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm<sup>3</sup> animals receiving compound II were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 4. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 4

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	scFv-tTF conjugate (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm<sup>3</sup> within 28 days (Figure 4) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm<sup>3</sup>. Tumors treated with the
- 10 coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound II, treatment group 3) grew to a volume of approx. 500 mm<sup>3</sup> within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex
- 15 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 400 mm<sup>3</sup> within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the

20 VEGF/VEGF receptor system over separate modes of intervention is clearly

shown. Similar effects can be expected upon targeting of cytotoxic agents to Angiopoietin/Tie receptor systems.

**Example 5**

Combination of functional interference with the Angiopoietin/Tie2 receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to  
 5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A fusion protein (L19 scFv-tTF) consisting of L19 single chain antibody specifically recognizing the oncofoetal ED-  
 10 B domain of fibronectin and the extracellular domain of tissue factor was expressed in E. coli as described by Nilsson et al. (Nat. Med., in press). Further, L19 scFv-tTF data have been represented by D. Neri and F. Nilsson (Meeting "Advances in the application of monoclonal antibodies in clinical oncology", Samos, Greece, 31. May-2. June 2000). When tumors reached a size of approx.  
 15 200 mm<sup>3</sup> animals receiving compound I were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 5. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

20

Table 5

treatment group	mode of treatment	
	L19 scFv-tTF (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+



Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm<sup>3</sup> within 28 days (Figure 5) without treatment (group 1). Tumors treated with the coagulation-inducing L19 scFv-tTF (compound I, treatment group 2) grew to a  
5 volume of approx. 450 mm<sup>3</sup> within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm<sup>3</sup>, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the endothelium with L19 scFv-tTF  
10 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm<sup>3</sup> within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

15

**Example 6**

Combination of functional interference with the VEGF/VEGF receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to  
5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-  
10 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of L19 scFv-tTF fusion protein as described in example 5. When tumors reached a size of approx. 200 mm<sup>3</sup> animals receiving compound II were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of  
15 treatment are described in Table 6. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 6

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	L19 scFv-tTF (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

5

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm<sup>3</sup> within 28 days (Figure 6) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a

10 reduction of the tumor volumes to approx. 550 mm<sup>3</sup>. Tumors treated with the coagulation-inducing L19 scFv-tTF targeted to the endothelium (compound II, treatment group 3) grew to a volume of approx. 450 mm<sup>3</sup> within 28 days.

Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate

15 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 200 mm<sup>3</sup> within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the VEGF/VEGF receptor system over separate modes of intervention is clearly shown.

5

10

### Description of the figures

Fig. 1 shows the superior effect of combination of interference with VEGF/VEGF receptor system by means of an specific tyrosine kinase inhibitor and with the  
 5 Angiopoietin/Tie2 receptor system by means of a soluble receptor domain on inhibition of tumor growth (treatment modes of groups 1-4 are given in Table 1).

The abbreviations have the following meaning:

	mock, con.	=	treatment group 1
	mock+VEGF-A	=	treatment group 2
10	sTIE2-cl13	=	treatment group 3
	sTIE2-cl13+VEGF-A	=	treatment group 4

Fig. 2 shows the superior effect on tumor growth inhibition of combination of  
 15 VEGF-neutralization and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 2).

20 Fig. 3 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 3).

25

Fig. 4 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-  
 30 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 4).

Fig. 5 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 5).

Fig. 6 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 6).

## CLAIMS

1. Pharmaceutical compositions comprising one or several agents as compound I  
which modulate the biological function of one or several of the VEGF/VEGF  
5 receptor systems, and comprising one or several agents as compound II which  
modulate the biological function of one or several of the Angiopoietin/Tie  
receptor systems.
2. Pharmaceutical compositions comprising one or several agents as compound I  
10 which are targeted to the endothelium via one or several of the VEGF/VEGF  
receptor systems, and comprising one or several agents as compound II which  
modulate the biological function of one or several of the Angiopoietin/Tie  
receptor systems.
- 15 3. Pharmaceutical compositions comprising one or several agents as compound I  
which modulates the biological function of one or several of the VEGF/VEGF  
receptor systems or of one or several of the Angiopoietin/ Tie receptor systems  
and comprising one or several agents as compound II which are targeted to  
the endothelium.
- 20 4. Pharmaceutical compositions comprising one or several agents as compound I  
which modulate the biological function of one or several of the VEGF/VEGF  
receptor systems, and comprising one or several agents as compound II which  
are targeted to the endothelium via one or several of the Angiopoietin/Tie  
25 receptor systems.
5. Pharmaceutical compositions comprising one or several agents as compound I  
which are targeted to the endothelium via one or several of the VEGF/VEGF  
receptor systems, and comprising one or several agents as compound II which  
30 are targeted to the endothelium via one or several of the Angiopoietin/Tie  
receptor systems.
6. Pharmaceutical compositions comprising one or several agents as compound  
I which modulate the biological function of one or several of the VEGF/VEGF

receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems.

- 5 7. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
- 10 8. Pharmaceutical compositions comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.
- 15 9. Pharmaceutical compositions according to claims 1-8 which are intended for simultaneous or separate sequential therapeutical application.
10. Pharmaceutical compositions according to claims 1-8 which comprise as compound I at least one of
- 20 a) compounds which inhibit receptor tyrosine kinase activity,  
b) compounds which inhibit ligand binding to receptors,  
c) compounds which inhibit activation of intracellular signal pathways of the receptors,  
d) compounds which inhibit or activate expression of a ligand or of a  
25 receptor of the VEGF or Tie receptor system,  
e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor  
30 systems,  
f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.



11. Pharmaceutical compositions according to claims 1-8 which comprise as compound II at least one of

- g) compounds which inhibit receptor tyrosine kinase activity,
- h) compounds which inhibit ligand binding to receptors,
- 5 i) compounds which inhibit activation of intracellular signal pathways of the receptors,
- j) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- 10 k) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- 15 l) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

12. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.


20

13. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II Seq. ID Nos. 34a

14. Pharmaceutical compositions according to claims 1-11 which comprise as  
25 compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTFconjugate.

15. Pharmaceutical compositions according to claims 1-11 which comprise as  
30 compound I and/ or II at least one small molecule of general formula I

41



I,

in which

5

r

has the meaning of 0 to 2,

n

has the meaning of 0 to 2;


R<sub>3</sub> und R<sub>4</sub>

a) each independently from each other have the meaning of lower alkyl,

10

b) together form a bridge of general partial formula

II,



II,

15

wherein the binding is via the two terminal C- atoms,


and

m

has the meaning of 0 to 4; or

c) together form a bridge of partial formula III

20



has wherein one or two of the ring members  $T_1, T_2, T_3, T_4$  the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms  $T_1$  and  $T_4$ ;

5 G has the meaning of  $C_1 - C_6$  - alkyl,  $C_2 - C_6$  - alkylene or  $C_2 - C_6$  - alkenylene; or  $C_2 - C_6$  - alkylene or  $C_3 - C_6$  - alkenylene, which are substituted with acyloxy or hydroxy;  $-CH_2-O-$ ,  $-CH_2-S-$ ,  $-CH_2-NH-$ ,  $-CH_2-O-CH_2-$ ,  $-CH_2-S-CH_2-$ ,  $-CH_2-NH-CH_2$ , oxa ( $-O-$ ), thia ( $-S-$ ) or imino ( $-NH-$ ),

10 A, B, D, E and T independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,

15 Q has the meaning of lower alkyl, lower alkyloxy or halogene,

$R_1$  and  $R_2$  independently from each other have the meaning of H or lower alkyl,

20 X has the meaning of imino, oxa or thia;

Y has the meaning of hydrogen, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and


25 Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl,

30 whereas, if more than one rest Z is present ( $m \geq 2$ ), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single

or double bonds; or an N-oxide of said compound,  
 wherein one or more N-atoms carry an oxygen atom,  
 or a salt thereof,

and/or a compound of general formula IV


5



in which

- A has the meaning of group  $=NR^2$ ,  
 W has the meaning of oxygen, sulfur, two hydrogen atoms  
 or the group  $=NR^8$ ,  
 Z has the meaning of the group  $=NR^{10}$  or  $=N-$ ,  $-N(R^{10})-$ ,  
 $(CH_2)_q$ , branched or unbranched  $C_{1-6}$ -Alkyl or is the  
 group


15



or A, Z and  $R^1$  together form the group

20


44



5	m, n and o	has the meaning of 0 – 3,
	q	has the meaning of 1 – 6,
	R <sub>a</sub> , R <sub>b</sub> , R <sub>c</sub> , R <sub>d</sub> , R <sub>e</sub> , R <sub>f</sub>	independently from each other have the meaning of hydrogen, C <sub>1-4</sub> alkyl or the group =NR <sup>10</sup> , and/or R <sub>a</sub> and/or R <sub>b</sub> together with R <sub>c</sub> and/or R <sub>d</sub> or R <sub>e</sub> together with R <sub>a</sub> and/or R <sub>f</sub> form a bound, or up to two of the groups R <sub>a</sub> -R <sub>f</sub> form a bridge with each up to 3 C-atoms with R <sup>1</sup> or R <sup>2</sup> ,
10	X	has the meaning of group =NR <sup>9</sup> or =N-,
	Y	has the meaning of group -(CH <sub>2</sub> ) <sub>p</sub> ,
	p	has the meaning of integer 1-4,
15	R <sup>1</sup>	has the meaning of unsubstituted or optionally substituted with one or more of halogene, C <sub>1-6</sub> -alkyl, or C <sub>1-6</sub> -alkyl or C <sub>1-6</sub> -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,
20	R <sup>2</sup>	has the meaning of hydrogen or C <sub>1-6</sub> -alkyl, or form a bridge with up to 3 ring atoms with R <sub>a</sub> -R <sub>f</sub> together with Z or R <sub>1</sub> ,
25	R <sup>3</sup>	has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally

$R^4, R^5, R^6$  and  $R^7$


substituted with one or more of für halogen,  $C_{1-6}$ -alkyl,  $C_{1-6}$ -alkoxy or hydroxy, independently from each other have the meaning of hydrogen, halogene or  $C_{1-6}$ -alkoxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogene, or  $R^5$  and  $R^6$  together form the group



$R^8, R^9$  and  $R^{10}$

independently from each other have the meaning of hydrogen or  $C_{1-6}$ -alkyl, as well as their isomers and salts,


and/ or a compound of general formula V



V,


in which

$R^1$  has the meaning of group




in which  $R^5$  is chloro, bromo or the group  $-OCH_3$ ,

5



in which  $R^7$  is  $-CH_3$  or chloro,



in which  $R^1$  is -CH<sub>3</sub>, fluoro,  
chloro or -CF<sub>3</sub>


in which  $R^2$  is fluoro,  
chloro, bromo, -CF<sub>3</sub>,  
-N=C, -CH<sub>3</sub>, -OCF<sub>3</sub> or  
-CH<sub>2</sub>OH

in which  $R^3$  is  
-CH<sub>3</sub> or chloro

5

$R^2$

has the meaning of pyridyl or the group



10

and

$R^3$

has the meaning of hydrogen or fluoro, as well as their  
isomers and salts.

16. Pharmaceutical compositions according to claim 15 which comprise as  
compound I and/ or II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate

17. Pharmaceutical compositions according to claims 1-16 which comprise as  
compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium  
hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF  
conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-  
phthalazin-1-yl]ammonium hydrogen succinate sTie2, mAB 4301-42-35, scFv-  
tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not  
identically to compound II.

25

18. Pharmaceutical compositions according to claims 1-17 which comprise as  
compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium



hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

19. Pharmaceutical compositions according to claims 1-17 which comprise as  
5 compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate.
20. Pharmaceutical compositions according to claims 1-17 which comprise as  
10 compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35.
21. Pharmaceutical compositions according to claims 1-17 which comprise as  
compound I L19 scFv-tTF conjugate and as compound II sTie2.
- 15 22. Use of pharmaceutical compositions according to claims 1-21, for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant  
20 nephrosclerosis, thrombic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6

## Sequence Identifier

5

&lt;110&gt; Schering Aktiengesellschaft

10 &lt;120&gt; Combinations and compositions which interfere with VEGF/ VEGF and angiopoietin/ Tie receptor function and their use II

&lt;130&gt; 51867AEPMLXX00-P

&lt;140&gt;

15 &lt;141&gt;

&lt;160&gt; 59

&lt;210&gt; 1

20 &lt;211&gt; 1835

&lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 1

25

```

ttttacagtt ttccttttct tcagagttta ttttgaattt tcatttttgg ataaccaagc 60
agctctttta gaagaatgca cagaagagtc attctggcac ttttggatag tacataagat 120
tttctttttt ttttttaaat tttttttaat agtcacattc agctcgcttg ctcaaaccag 180
actcccacat tgggtgagca agatgagccc ataggattcc agagttaata cgtaaccgta 240
30 tatacaaaaca gccaaaaaac cataatgggt ccacagggat ggagcagggg agggcatctc 300
taacgtgtcc tctagtctat cttcgctaaa cagaaccac gttacacatg ataactagag 360
agcacactgt gttgaaacga ggatgctgac ccaaattggc acttggcagc atgcagttta 420
aagcaaaaga gacatccttt aataactgta taaaatccag gcagttccat taaaggggtt 480
aagaaaacca acaacaacaa aaagcgaggg actgtctgtt gtcactgtca aaaaggcact 540
35 tggagttaat gggaccagga ttggaggact cttagctgat acagatttca gtacgatttc 600
attaaaaggc ttggatgtta agagaggaca ctcagcggtt cctgaaggga gacgctgaga 660
tggaccgctg agaagcggaa cagatgaaca caaaggaaatc aaatctttac aaccaaattg 720
catttaagcg acaacaaaaa aaggcaaac ccacaaacgca acctaacca agcaaaatct 780
aagcaaaatc agacaacgaa gcagcgatgc atagctttcc tttgagagaa cgcatacctt 840
40 gagacgctac gtgccaacct aagttctcaa cgacagcttc acagtaggat tattgtgata 900
aaaatgactc aagcgatgca aaaagtttca tctgttccca gaatccgagg gagaactgag 960
gtgatcgta gagcatagcg acatcacgtg cggtttctta atgtccctgg tggcggatac 1020
gccgagtcct cggaaggaca tctggacacc actttcagcc acctccttgc aggggcgaca 1080
tccgccaaag tcatccttta ttccgagtaa taactttaat tcctttctaa catttacacg 1140
45 gcaaacagga atgcagtaaa cgtccacgtc cgtcccacgg ctgggctgcc gttccgtttc 1200
ctccacgaac gggtagcgcg ttccatgaga aaggatattt ggcaatttta tattccacag 1260
tcaggtgggt ctgcgatagc tcatttaatg ttaaagccca tcaggggcct ctctcccgt 1320
ttctgccagg ggcttttctt gtcttctcct tggcgagctc gtgggcagat cttctctggt 1380
gggggctggc tgctggctcc gagggggcat ccgcagtcog tctggtcgtc tcctcctgca 1440
50 ggctgggcag ctggccacca cttctccgac cgcacccctc caacaagcat cgcagggcac 1500
tgtctcggg ggtacagacc gtggtccac attcgctacc actctgttcc acgtcatcca 1560
ggtacacgag ctgctgttag gccgtgctgt ctggggctcg aggctcttcc tgctgggtgt 1620
cttgacggg cgggtagttc tgctgcagag acaaagcatc tccccttccc ttccgggctg 1680
attttggttc attcatatct acgccagagt ccaaactggc atcattactt ccgttccttc 1740
55 cagctctttg gagaatcaat gtatgaatgt ctaacctgac cgttggacct gccatccaag 1800
gagacgaacc acgcccgggg gtgcggaagc ggcct

```

&lt;210&gt; 2

60 &lt;211&gt; 581

&lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 2

5 gttctagatt gttttattca gtaattagct ctttaagaccc ctggggcctg tgctacccag 60  
 acactaaca cagtctctat ccagttgctg gttctgggtg acgtgatctc cccatcatga 120  
 tcaacttact tcctgtggcc cattagggaa gtggtgacct cgggagctat ttgcctgttg 180  
 agtgcacaca cctggaaaca tactgctctc attttttcat ccacatcagt gagaaatgag 240  
 tggcccggtta gcaagatata actatgcaat catgcaacaa agctgcctaa taacatttca 300  
 10 tttattacag gactaaaagt tcattattgt ttgttaaagga tgaattcata acctctgcag 360  
 agttatagtt catacacagt tgattttccat ttataaaggc agaaagtcct tgttttctct 420  
 aaatgtcaag ctttgactga aaactcccgt ttttccagtc actggagtgt gtgcgtatga 480  
 aagaaaatct ttagcaatta gatgggagag aagggaata gtacttgaaa tgtaggccct 540  
 cacctcccca tgacatcctc catgagcctc ctgatgtagt g

15 <210> 3  
 <211> 516  
 <212> DNA  
 <213> Human

&lt;400&gt; 3

20 tagagatggt ggttgatgac ccccgggatc tggagcagat gaatgaagag tctctggaag 60  
 tcagcccaga catgtgcatc tacatcacag aggacatgct catgtcgcgg aacctgaatg 120  
 25 gacactctgg gttgattgtg aaagaaattg ggtcttccac ctcgagctct tcagaaacag 180  
 ttgttaagct tcgtggccag agtactgatt ctcttcacac gactatatgt cggaaaccaa 240  
 agacctccac tgatcgacac agcttgagcc tcgatgacat cagactttac cagaaagact 300  
 tcctgcgcat tgcaggtctg tgtcaggaca ctgctcagag ttacaccttt ggatgtggcc 360  
 atgaactgga tgaggaaggc ctctattgca acagttgctt ggcccagcag tgcataca 420  
 30 tccaagatgc ttttccagtc aaaagaacca gcaaataactt ttctctggat ctactcatg 480  
 atgaagtccc agagtttgtt gtgtaaagtc cgtctg

<210> 4  
 <211> 1099  
 <212> DNA  
 35 <213> Human

&lt;400&gt; 4

40 cccacaacac aggggccctg aaacacgcca gcctctctc tgtggtcagc ttggcccagt 60  
 cctgctcact ggatcacagc ccattgtagg tggggcatgg tggggatcag ggcccctggc 120  
 ccacggggag gtagaagaag acctggtccg tgtaaggggc tgagaagggtg ccctgggtcg 180  
 ggggtgcgtc ttggccttgc cgtgccctca tccccgggt gaggcagcga cacagcaggt 240  
 gcaccaactc cagcagggtta agcaccagg agatgagtc aaccaccaac atgaagatga 300  
 45 tgaagatggt cttctccgtg gggcgagaga caaagcagtc cagcaggtag gggcaggggtg 360  
 ctgctggca cacaacacg ggctccatgg tccagccgta caggcgccac tggccataga 420  
 ggaagcctgc ctctagcaca ctcttgaga gcacactggc gacatagggtg cccatcagt 480  
 ctccgcggtat gcgcaggcga ccactctctg ccaccgagat cttggccatc tgacgctcta 540  
 cgcccgccag cgcccgctcc acctgtgggt ccttgccgg cagtgcgccg agctccccct 600  
 50 cttctgccc cagccgctct tctcgccgag acaggtaaat gacatggccc aggtagacca 660  
 ggggtgggtgt gctgacgaag aggaactgca gcaccagta gcggatgtgg gagatgggga 720  
 aggcctgggt atagcagacg ttggtgcagc ctggctgggc cgtgttacac tcgaaatctg 780  
 actgctcgtc accccacact gactcgccgg ccaggcccag gatgaggatg cggaagatga 840  
 agagcaccgt cagccagatc ttaccaccca cggtcgagt ctcctggacc tggccagca 900  
 55 acttctccac gaagccccag tcaccatgg ctcccgggc tccgtcggca aggagacaga 960  
 gcacgtcagt gtgtcagcat ggcatccttc tcgttcgccc agcaacaagc ctgcagggag 1020  
 gtctgccacg ccggttctac cgcctgctg ccgggcggcc caggtggag tggggacgat 1080  
 ggccggagtg acgcccgcg

<210> 5  
 60 <211> 1015  
 <212> DNA  
 <213> Human

&lt;400&gt; 5

65 gaggataggg agcctgggggt caggagtgtg ggagacacag cgagactctg tctccaaaaa 60

	aaaaagtgc	ttttgaaat	gttgaggttg	aaatgatggg	aaccaacatt	ctttggattt	120
	agtggggagc	ataatagcaa	acacccccctt	ggttcgcaca	tgtacaggaa	tgggacccag	180
	ttggggcaca	gccatggact	tccccgccct	ggaatgtgtg	gtgcaaaagt	ggggcagggc	240
5	ccagacccaa	gaggagaggg	tggtcgcag	acaccccg	atgtcagcat	ccccgacct	300
	gccttctggc	ggcacctccc	gggtgctgtg	ttgagtcagc	aggcatgggg	tgagagcctg	360
	gtatatgctg	ggaacaggg	gcaggggcca	agcgttcctc	cttcagcctt	gacttggggc	420
	atgcaccccc	tctccccaa	acacaaacaa	gcacttctcc	agtatggtgc	caggacaggt	480
	gtcccttcag	tctcttggtt	atgacctcaa	gtcctacttg	ggccctgcag	cccagcctgt	540
	gttgtaacct	ctgcgtcctc	aagaccacac	ctggaagatt	cttcttccct	ttgaaggaga	600
10	atcatcattg	ttgctttatc	acttctaaga	cattttgtac	ggcacggaca	agttaaacag	660
	aatgtgcttc	cctccctggg	gtctcacacg	ctccacagag	aatgccacag	gggcccgtgc	720
	ctgggcaggc	ttctctgtag	aaccccagg	gcttcggccc	agaccacagc	gtcttgccct	780
	gagcctagag	cagggagtc	cgaacttctg	cattcacaga	ccacctccac	aattgttata	840
	accaaaggcc	tctgtttctg	ttatttcaat	taaatcaaca	tgctattttg	ttttcactca	900
15	cttctgactt	tagcctcgtg	ctgagccgtg	tatccatgca	gtcatgttca	cgtgctagtt	960
	acgtttttct	tcttacacat	gaaaataaat	gcataagtgt	tagaagaaaa	aaaaa	
	<210> 6						
	<211> 2313						
20	<212> DNA						
	<213> Human						
	<400> 6						
25	ccagagcagg	cctggtggtg	agcagggagc	gtgcaccgga	cggcgggatc	gagcaaatgg	60
	gtctggccat	ggagcacgga	gggtcctacg	ctcggggcgg	gggcagctct	cggggctgct	120
	ggtattacct	gcgctacttc	tctctcttcg	tctccctcat	ccaattcctc	atcatcctgg	180
	ggctcgtgct	cttcatggtc	tatggcaacg	tgcacgtgag	cacagagtcc	aacctgcagg	240
	ccaccgagcg	ccgagccgag	ggcctataca	gtcagctcct	agggctcacg	gcctcccagt	300
30	ccaacttgac	caaggagctc	aacttcacca	cccgcgcca	ggatgccatc	atgcagatgt	360
	ggctgaatgc	tcgcccgcgac	ctggaccgca	tcaatgccag	cttcgcgcag	tgccagggtg	420
	accgggtcat	ctacacgaac	aatcagaggt	acatggctgc	catcatcttg	agtgagaagc	480
	aatgcagaga	tcaattcaag	gacatgaaca	agagctgcga	tgcttgcctc	ttcatgctga	540
	atcagaaggt	gaagacgctg	gaggtggaga	tagccaagga	gaagaccatt	tgactaagg	600
35	ataaggaaag	cgtgctgctg	aacaaacgcg	tggcggagga	acagctggtt	gaatgcgtga	660
	aaacccggga	gctgcagcac	caagagcgcc	actggccaag	gagcaactgc	aaaagggtgc	720
	agccctctgc	ctgcccttgg	acaaggacaa	gtttgagatg	gaccttcgta	acctgtggag	780
	ggactccatt	atcccacgca	gcctggacaa	cctgggttac	aacctctacc	atcccctggg	840
	ctcggaattg	gcctccatcc	gcagagcctg	cgaccacatg	cccagcctca	tgagctccaa	900
40	ggtggaggag	ctggcccggg	gcctccgggc	ggatatcgaa	cgcgtggccc	gcgagaactc	960
	agacctccaa	cgccagaagc	tggaaagcca	gcaggccctg	cgggccagtc	aggaggcgaa	1020
	acagaaggtg	gagaagagg	ctcaggcccc	ggaggccaag	ctccaagctg	aatgctccc	1080
	gcagacccag	ctagcgtctg	aggagaaggc	ggtgctgcgg	aaggaacgag	acaacctggc	1140
	caaggagctg	gaagagaaga	agagggaggc	ggagcagctc	aggatggagc	tggccatcag	1200
45	aaactcagcc	ctggacacct	gcatacaagc	caagtgcag	ccgatgatgc	cagtgtcaag	1260
	gcccattggg	cctgtcccca	accccagcc	catcgacca	gctagcctgg	aggagttcaa	1320
	gaggaagatc	ctggagtccc	agaggcccc	tgcaggcatc	cctgtagccc	catccagtgg	1380
	ctgaggaggc	tccaggcctg	aggaccaagg	gatggcccga	ctcggcggtt	tgccgaggat	1440
	gcagggatat	gctcacagcg	cccagacaaa	ccccctccc	ccgcccccaa	ccaccagg	1500
50	ccaccatcag	acaactccct	gcatacaaac	ccctagtacc	ctctcacacc	cgcacccg	1560
	cctcacgac	cctcaccag	agcacacggc	cgcgagatg	acgtcacgca	agcaacggc	1620
	ctgacgtcac	atatcacctg	ggtgatggcg	tcacgtggcc	atgtagacgt	cacgaagaga	1680
	tatagcgatg	gcgtcgtgca	gatgcagcac	gtcgcacaca	gacatgggga	acttggcatg	1740
	acgtcacacc	gagatgcagc	aacgacgtca	cgggccatgt	cgacgtcaca	catattaatg	1800
55	tcacacagac	gcggcgatgg	catcacacag	acggtgatga	tgtcacacac	agacacagtg	1860
	acaacacaca	ccatgacaac	gacacctata	gatattggac	caacatcaca	tgacgcgtat	1920
	ccctttcaca	cacactttct	acccaattct	cacctagtgt	cacgttcccc	cgacctggc	1980
	acacgggcca	aggtacccac	aggatcccat	ccccctccgc	acagccctgg	gccccagcac	2040
	ctccctcct	ccagcttct	ggcctccag	ccacttcctc	acccccagtg	cctggacccg	2100
60	gaggtgagaa	cagggaagcca	ttcacctccg	ctccttgagc	gtgagtggtt	ccaggacccc	2160
	ctcggggccc	tgagccgggg	gtgaggtgca	cctgttgcgc	ggaggggagc	cactccttct	2220
	ccccaacac	ccagccctgc	ctgtggccc	ttgaaatgtt	ggtggcactt	aataaatatt	2280
	agtaaactct	taaaaaaaaa	aaaaaaaaaa	aaa			
65	<210> 7						
	<211> 389						



<212> DNA  
<213> Human

<400> 7

5 gccaaaaaga tggcttcaaa agtaagaatg aaacatttga tccattcagc tttaggctat 60  
gccactggat tcatgtctag aaaagatagg ataatttctg taaagaaatg aagaccttgc 120  
tattctaaaa tcagatcctt acagatccag atttcaggaa acaaatacat aggggactaa 180  
10 ctttccttgt tcagattagt ttttctcctt tgcacccagc tatataatat gaggaagtat 240  
tgacttttta aaagtgtttt agttttccat ttctttgata tgaaaagtaa tatttcggga 300  
gaaccctgag ctattaataa tctatgtggc tagtgcgtat atattggctc gaatttggtc 360  
tccttttgtg gtgtccagtg ggtaacatc

<210> 8  
<211> 157  
<212> DNA  
<213> Human

<400> 8

20 tgctttaaac agctgtgtca aaaactgaca tcagagagta aattgaattt ggttttgtag 60  
gaagcaggaa gcaagccac tcaaactgta aatttggcat gagggatcca gtaactttct 120  
cctcaatctg tgaactatat gtgagtttga tattttg

25 <210> 9  
<211> 561  
<212> DNA  
<213> Human

30 <400> 9

aatagtcaaa acataaacia aagctaatta actggcactg ttgtcacctg agactaagtg 60  
gatgttgttg gctgacatac aggtcagcc agcagagaaa gaattctgaa ttccccttgc 120  
35 tgaactgaac tattctgtta catatggttg acaaactctgt gtgttatttc ttttctacct 180  
accatattta aatttatgag tatcaaccga ggacatagtc aaaccttcga tgatgaacat 240  
tcctgatttt ttgcctgatt aatctctgtt gagctctact tgtggtcatt caagatttta 300  
tgatgttgaa aggaaaagtg aatatgacct ttaaaaattg tattttgggt gatgatagtc 360  
tcaccactat aaaactgtca attattgcct aatgttaaag atatccatca ttgtgattaa 420  
40 ttaaacctat aatgagtatt cttaatggag aattcttaat ggatggatta tcccctgatc 480  
ttttctttta aatttctctg cacacacagg acttctcatt ttccaataaa tgggtgtact 540  
ctgccccaat ttctaggaaa a

<210> 10  
<211> 1508  
<212> DNA  
<213> Human

<400> 10

50 cacaaacacg agagactcca cgtctgcct gagcaccgcc agcctcctag gctccagcac 60  
tcgcaggctc attcttctgc acgagcctct ctgtccagat ccataagcac ggtcagctca 120  
gggtcgcgga gcagtacgag gacaagtacc agcagcagct cctctgaaca gagactgcta 180  
ggatcatcct tctcctccgg gcctgttgct gatggcataa tccgggtgca acccaaactc 240  
55 gagctcaagc caggtgagct taagccactg agcaaggaa atttggcct gcacgcctac 300  
aggtgtgagg actgtggcaa gtgcaaatgt aaggagtgc cctaccaag gcctctgcca 360  
tcagactgga tctgcgacaa gcagtgcctt tgctcggccc agaactgat tgactatggg 420  
acttgtgtat gctgtgtgaa aggtctcttc tatcactggt ctaatgatga tgaggacaac 480  
tgtgtctgaca acccatgttc ttgcagccag tctcactggt gtacacgatg gtcagccatg 540  
gggtgtcatgt cctctctttt gccttgttta tgggtgtacc ttccagccaa gggttgcctt 600  
60 aaattgtgcc aggggtgtta tgaccgggtt aacaggcctg gttgccgctg taaaaactca 660  
aacacagttt gctgcaaagt tcccactgtc ccccctagga actttgaaa accaactatg 720  
catcattaat caggaatatt acagtaatga ggattttttc tttctttttt taatacacat 780  
atgcaaccaa ctaaacagtt ataactcttg cactgttaat agaaagtgtg gatagtcttt 840  
gctgttttgcg gtgaaatgct ttttgtccat gtgcccgttt aactgatatg cttgttagaa 900  
65 ctcagcta at ggagctcaaa gtatgagata cagaacttgg tgacccatgt attgcataag 960  
ctaaagcaac acagacactc ctaggcaaa tttttgtttg tgaatagtag ttgcaaaact 1020

5 tgtaaattag cagatgactt ttttccattg ttttctccag agagaatgtg ctatatTTTT 1080  
 gtatatataa taatatTTTgc aactgtgaaa aacaagtggg gccatactac atggcacaga 1140  
 cacaaaaatat tataactaata tgttgtagat tcggaagaat gtgaatcaat cagtatgttt 1200  
 ttagattgta ttttgcctta cagaaagcct ttattgtaag actctgattt ccctttggac 1260  
 10 ttcattgtata ttgtacagtt acagtataaat tcaaccttta ttttctaatt ttttcaacat 1320  
 attgtttagt gtaaagaata tttatttgaa gttttattat tttataaaaa agaattttta 1380  
 ttttaagagg catcttataa attttgcccc ttttatgagg atgtgatagt tgctgcaaat 1440  
 gaggggttac agatgcatat gtccaatata aaatagaaaa tatattaacg tttgaaatta 1500  
 aaaaaaaa  
 <210> 11  
 <211> 389  
 <212> DNA  
 <213> Human  
 15 <400> 11  
 20 gggcagggtga tcagggcaca catttcccgt ccattgagac agtagcattc ccggcaccca 60  
 tcgtgccagc tctcctcatt tttatgatga tgaccatcca cggtagagaca agtgcccagc 120  
 aggatgggtg gccagctga agcacaggcc gctctgcact tgcagataag acagccgtga 180  
 ctgtcctgct ggaaacccaa ggggcagatc ttactgcatg agagctctgg acatttctta 240  
 cagcgacaga gtgcacagcc gtgcttattc ttcagcaatc caagtggaca atacttgtca 300  
 cagattatgg gtctgcactt cttgggcctt gggcggcact cacagatctc acagttttgg 360  
 25 acctcggccg cgaccacgct gggtagcga  
 <210> 12  
 <211> 981  
 <212> DNA  
 <213> Human  
 30 <400> 12  
 35 tttttttttt ttggattgca aaaattttatt aaaattggag aactgtttt aatcttcttg 60  
 tgccatgaga ctccatcagg cagtctacaa agaccactgg gaggtgagg atcacttgag 120  
 cccagaagtt tgaggctgta gtaagcttca aaggccactg cactctagct tgggtgaggc 180  
 aagacccttt caagcagtaa gctgcatgct tgcttgttgt ggtcattaaa aaccctagtt 240  
 taggataaca acatattaat caggggcaaaa tacaattgtg tgatgcttgt tagtagagta 300  
 acctcagaat caaaatggaa cggttttaca gtgatatcat tatatttcat ttggcagaat 360  
 cattacatca ttggttacac tgaaaatcat cacatgtacc aaaagctgac tcacctagtt 420  
 40 taggataaca ggtctgcctg tttgaagatg aaaaataata cccattttaa atttgcccta 480  
 ctcaatttcc ttctcagtca cattttaact tttaaacagc taatcactcc catctacaga 540  
 ttaagggtga tatgccacca aaaccttttg ccacctttaa aatttccttc aaagttttaa 600  
 ctaatgcctg catttcttca atcatgaatt ctgagtcctt tgettcttta aaacttgctc 660  
 cacacagtgt agtcaagccg actctccata cccaagcaag tcatccatgg ataaaaactg 720  
 45 taccaggagc agaaccatta agctggtcca ggcaagttgg actccaccat ttcaacttcc 780  
 agctttctgt ctaatgcctg tgtgccaatg gcttgagtta ggcttgctct ttaggacttc 840  
 agtagctatt ctcatccttc cttgggggaca caactgtcca taagggtgcta tccagagcca 900  
 cactgcatct gcacccagca ccatacctca caggagtcga ctcccacgag ccgcctgtat 960  
 50 ataagagttc ttttgatgac g  
 <210> 13  
 <211> 401  
 <212> DNA  
 <213> Human  
 55 <400> 13  
 60 ataactacag cttcagcaga caactaaaga gactgcatta aggtgatttc tctggctata 60  
 aagagagccc ggccgcagag catgtgactg ctgggacctc tgggataggc aacactgccc 120  
 tctctccccc agagcgaccc cccgggcagg tcggggccca aggaatgacc cagcaactgc 180  
 tccctaccca gcacactctc tttactgcca cctgcaatta tgctgtgaag atgactgggt 240  
 gtgggtcatca cgattcagag aaatcaagat ctatgacat tttaggcaaa gagagaaact 300  
 tggagaattg ctgaggacta ctgaaccttg ttttgctttt ttaaaaaata ctaaatcctc 360  
 65 acttcagcat atttagttgt cattaaaatt aagctgatat t  
 <210> 14

<211> 1002  
 <212> DNA  
 <213> Human

5 <400> 14

gacaatataa aaagtggaaa caagcataaa ttgcagacat aaaataatct tctggtagaa 60  
 acagtgtggt agaacagggt gagtagagca acaacaacaa aagcttatgc agtcaccttc 120  
 10 tttgaaaatg ttaaatacaa gtcctattct ctttgtccag ctgggttttag ctagaggtag 180  
 ccaattactt ctcttaagggt ccatggcatt cgccaggatt ctataaaagc caagttaact 240  
 gaagtaaata tctggggccc atcgaccccc cactaagtac tttgtcacca tgttgtatct 300  
 taaaagtcac ttttctactgt ttgactcaga atttgggact tcagagtcaa acttcattgc 360  
 ttactccaaa ccaggtttta ttccccactt ttttaagtag gcttagcttt gactgatttt 420  
 tggctataac cgaaatgtaa atccaccttc aaacaacaaa gtttgacaag actgaaatgt 480  
 15 tactgaaaac aatggtgcca tatgtcctaa agacatttcc ccaagataac tgccaaagag 540  
 tttttgagga ggacaatgat catttattat gtaggagcct tgatatctct gcaaaataga 600  
 attaatacag ctcaaagga gtagtaacca agcttttctg ccaggaagt aacaaacatc 660  
 actacgaaca tgagagtaca agaggaaact ttcataatgc attttttcat tcatacatctc 720  
 attcaataaa cattagccaa gctaattgtc caagccactg tgccaggat taacaatata 780  
 20 acaacaataa aagacacagt ccttcctctc aagggtgtca gtctagtagg gaagatgatt 840  
 attcattaaa atttttggtg catcagaatc atgaggagct tgtcaaaaat gtaattcct 900  
 gcctatgttc tcagatattc tggttagggtc aggagtggga acccaaaatc aattctttta 960  
 acaaacacta aaggtgattc taacacaggc ggtgtgagga cc

25 <210> 15  
 <211> 280  
 <212> DNA  
 <213> Human

30 <400> 15

cgagggtgggc caccctgtgc tgggtctgaga tttttaaatg aggattacat tctctatttt 60  
 ataataattcc tattctaatc tattgtattc ttacaattaa atgtatcaaa taattcttaa 120  
 35 aaacattatt agaaacaaac tgcctaatac cttataagac taaaaaaatc accaagatga 180  
 aactgtatta tgactctcaa tatttaaaca tttaaaaaaa tgttagtggt tgttaagcac 240  
 caatcttaac tatttcacct gcccgggcgg ccgctcgagg

<210> 16  
 <211> 2041  
 40 <212> DNA  
 <213> Human

<400> 16

45 cccccgcag aactcccccc tggaaatagga tttttaaaac ccttgacaat tagaaatcct 60  
 atagagggtta gcatttttta ggtaaaaata tgggtgcccc tacagggatc atgcaacttc 120  
 cttaaaacca attcagcaca tatgtataaa gaaccctttt taaaaacatt tgtacttgaa 180  
 atacagacac agtgatgctg aagacactaa acaaaaactg aaaagtacta taccttgata 240  
 50 aattttgtta ttgccttctt tagagacttt ataactctta gttgattttc aaggacttga 300  
 atttaataat ggggtaatta cacaagacgt aaaggatttt taaaaaaca gtattttttt 360  
 ttacctctag catcaattct tttataaaga atgctaaata aattacattt tttgttcagt 420  
 aaaactgaag atagaccatt taaatgcttc taccaaattt aacgcagctt aattagggac 480  
 caggtaacata ttttcttctg aacatttttg gtcaagcatg tctaaccata aaagcaaatg 540  
 gaattttaag aggtagattt tttttccatg atgcattttg ttaataaatg tgtcaagaaa 600  
 55 ataaaaacaa gcaactgagtg ttttctcttg aagtataagg gtctaataag aaataaaaaga 660  
 tagatatttg ttatagtctg acatttttaac agtcatagta ttagacgttt cgtgaccagt 720  
 gcatttttga ctctctcagg atcaaaaatac gactctgcca actgtattta atcctcctcc 780  
 accccctcca ccagttggtc cacagcttcc tgggtgggtc ttgtcatcaa atccattggg 840  
 ccgaaatgaa catgaagcag atgcagcttg gagggcccg gctcgagcat tcaactcttg 900  
 60 ttcctgtaaa tatagtttat tgtcttttgt tatagcatcc ataagttctt tctgtagagg 960  
 tgggtctcca tttatccaga gtccactggg tgggttatta ccacttaaac cattagtact 1020  
 atgctgtttt ttatacaaaa gcacataaag tgtgtccttt ggaaacctgc tcgtaatttt 1080  
 ctggactgac tgaatgaag taaatgtcac tctactgtca ttaataaaaa acccattctt 1140  
 ttgacatttc cttattttcc aaatcctgtt caaaaactgc actgggacta tctctcccta 1200  
 65 gtaaatgact ctgggaggat gctaattgcca gagcctcaga ctgggtgtac atctgatatg 1260  
 aagagtctgt acttgtgata tttctggcat aagaatagta atgccactt tcagaggata 1320

	taccagagt	g	aaccacaacg	gaacttaata	gatagggcac	caat	ttt	gtg	caggaagctt	1380
	catcagtc	ccc	tgaaggttt	aat	tttttag	caaggttctc	actaagatca	gtgaagtcaa	1440	
	catctacaga	ccaactttct	gacaatgaag	agaaagaagt	aattcttcta	actggcaact	1500			
5	ccaaaaccag	tggccagtga	tacattgtct	aaaat	tttcc	ttctcacatg	atacttctga	1560		
	tcatatgaaa	atctcaggag	agtaagaata	aggat	tttcag	gttccctccgt	gatttgcata	1620		
	gttttctcag	cattttgcag	agaggcacag	ttttcacaat	aattattggtt	atcaccagta	1680			
	agaatctctg	gagcccaaaa	aataat	tttag	taagt	cagtt	actgaagg	tggtttcacc	1740	
	tcccggtttc	tgaggtacat	ctttattaac	aagaatcttg	ttagattcgt	tagggacaga	1800			
	agtgttttca	gaacagtaaa	actcattagg	aggactgcct	atgggttttt	cattcacaag	1860			
10	tgagtcacag	atgaaggcag	ctgttggttg	attataaaact	actggctctt	ctgaaggacc	1920			
	gggtacagac	gcttgcatta	gaccaccatc	ttgtatactg	ggtgatgatg	ctggatcttg	1980			
	gacagacatg	ttttccaaag	aagaggaagc	acaaaacgca	agcgaaagat	ctgtaaaggc	2040			
	t									
15	<210>	17								
	<211>	235								
	<212>	DNA								
	<213>	Human								
20	<400>	17								
	cgccccgggc	aggtgtcagg	ggttccaaac	cagcctgggg	aaacacagcg	tagacccctc	60			
	acctctacaa	ataaaaaatt	aaaaaattag	ccaggtgtgg	cagcgaacaa	ctgtagcttc	120			
25	agatactcag	gagactgagc	tggaaggat	cacttgagcc	caagaagttc	aaggttacag	180			
	tgggccacga	tcatgtcatt	acactccagc	ttgggtgaca	aaatgagact	gtcta				
	<210>	18								
	<211>	2732								
	<212>	DNA								
30	<213>	Human								
	<400>	18								
	gtgtggagtt	tcagctgcta	ttgactataa	gagctatgga	acagaaaaag	cttgcctggct	60			
35	tcatgttgat	aactacttta	tatggagctt	cattggacct	gttaccttca	ttattctgct	120			
	aaatattatc	ttcttgggtga	tcacattgtg	caaaatgggtg	aagcattcaa	acactttgaa	180			
	accagattct	atgcaggttg	aaaacattaa	gtcttgggtg	cttggcgctt	tcgctcttct	240			
	gtgtcttctt	ggcctcacct	ggtccttttg	gttgcttttt	attaatgagg	agactattgt	300			
	gatggcatat	ctcttcacta	tatttaatgc	tttcaggga	gtgttcattt	tcatctttca	360			
40	ctgtgctctc	caaaagaaag	tacgaaaaga	atatggcaag	tgcttcagac	actcatactg	420			
	ctgtggaggc	ctcccaactg	agagtcccca	cagttcagtg	aaggcatcaa	ccaccagaac	480			
	cagtgctcgc	tattctctcg	gcacacagag	tcgtataaga	agaatgtgga	atgatactgt	540			
	gagaaaacaa	tcagaatctt	cttttatctc	aggtgacatc	aatagcactt	caacacttaa	600			
	tcaaggtggc	ataaatctta	atatattatt	acaggactga	catcacatgg	tctgagagcc	660			
45	catcttcaag	atttatatca	tttagaggac	attcactgaa	caatgccagg	gatacaagtg	720			
	ccatggatac	tctaccgcta	aatggtaatt	ttaacaacag	ctactcgtg	cacaaggggtg	780			
	actataatga	cagcgtgcaa	gttggtgact	gttgactaag	tctgaatgat	actgcttttg	840			
	agaaaatgat	catttcagaa	ttagtgcaca	acaacttacg	gggcagcagc	aagactcaca	900			
	acctcgagct	cacgctacca	gtcaaacctg	tgattggagg	tagcagcagt	gaagatgatg	960			
50	ctattgtggc	agatgcttca	tctttaatgc	acagcgacaa	cccagggtcg	gagctccatc	1020			
	acaaagaact	cgaggcacca	cttattcctc	agcggactca	ctcccttctg	taccaacccc	1080			
	agaagaaagt	gaagtccgag	ggaactgaca	gctatgtctc	ccaactgaca	gcagaggctg	1140			
	aagatcacct	acagtccccc	aacagagact	ctctttatac	aagcatgccc	aatcttagag	1200			
	actctcccta	tccggagagc	agccctgaca	tggaagaaga	cctctctccc	tccaggagga	1260			
55	gtgagaatga	ggacattttac	tataaaagca	tgccaaatct	tgagagctggc	catcagcttc	1320			
	agatgtgcta	ccagatcagc	aggggcaata	gtgatgggtta	tataatcccc	attaacaaag	1380			
	aagggtgtat	tccagaagga	gatgttagag	agagacaaat	gcagctggtt	acaagtcttt	1440			
	aatcatacag	ctaaggaatt	ccaagggcca	catgcgagta	ttaataaata	aagacaccat	1500			
	tggcctgacg	cagctccctc	aaactctgct	tgaagagatg	actcttgacc	tgtgggttctc	1560			
60	tgggtgtaaaa	aagatgactg	aaccttgacg	ttctgtgaat	ttttataaaa	catacaaaaa	1620			
	ctttgtatat	acacagagta	tactaaagtg	aattat	tttgt	tacaaaagaa	agagatgcca	1680		
	gccagggtatt	ttaagattct	gctgtgtgtt	agagaaattg	tgaacaagc	aaaacaaaac	1740			
	tttccagcca	ttttactgca	gcagtctgtg	aactaaat	ttt	gtaaatatgg	ctgcaccatt	1800		
	tttgtaggcc	tgcattgtat	tatatacaag	acgtaggctt	taaaatcctg	tggaacaaat	1860			
65	ttactgtacc	ttactattcc	tgacaagact	tggaaggaagc	ggagagatat	tctgcatcag	1920			
	tttgcagttc	actgcaaatc	ttttacatta	aggcaagat	tgaacacatg	cttaaccact	1980			

	agcaatcaag	ccacaggcct	tatttcatat	gtttcctcaa	ctgtacaatg	aactattctc	2040
	atgaaaaatg	gctaaagaaa	ttatatatttg	ttctattgct	agggtaaaaat	aaatacattt	2100
	gtgtccaact	gaaatataat	tgatcattaaa	ataatttttaa	agagtgaaga	aaatattgtg	2160
5	aaaagctctt	ggttgccat	ggtatgaaat	gttttttctt	acactttgtc	atggtaagtt	2220
	ctactcattt	tcacttcttt	tccactgtat	acagtgttct	gctttgacaa	agttagctt	2280
	tattactttac	atttaaattt	cttattgcc	aaagaacgtg	ttttatgggg	agaaacaaac	2340
	tctttgaagc	cagttatgtc	atgccttgca	caaaagtgat	gaaatctaga	aaagattgtg	2400
	tgtaacccct	gtttattctt	gaacagaggg	caaagagggc	actgggcaact	tctcacaaac	2460
	tttctagtga	acaaaagggtg	cctattcttt	tttaaaaaaa	taaaataaaa	cataaatatt	2520
10	actcttccat	attccttctg	cctatatatta	gtaattaatt	tattttatga	taaagttcta	2580
	atgaaatgta	aattgtttca	gcaaaattct	gctttttttt	catccctttg	tgtaaacctg	2640
	ttaataatga	gccccact	aatatccagt	gtaaagttta	acacggtttg	acagtaaata	2700
	aatgtgaatt	ttttcaagtt	aaaaaaaaaa	aa			
15	<210> 19						
	<211> 276						
	<212> DNA						
	<213> Human						
20	<400> 19						
	ctccctaaat	gatttttaaaa	taaattggat	aaacatatga	tataaagtgg	gtactttaga	60
	aaccgccttt	gcatattttt	tatgtacaaa	tctttgtata	caattccgat	gttccttata	120
25	tattccctat	atagcaaac	aaaaccagga	cctcccaact	gcatgcctca	agtcctctg	180
	gagcactctg	gcaactggat	ggccctactt	gctttctgac	aaaatagctg	gaaaggagga	240
	gggaccaatt	aaatacctcg	gcccgcgacca	cgctgg			
	<210> 20						
	<211> 2361						
30	<212> DNA						
	<213> Human						
	<400> 20						
35	attgtaccag	ccttgatgaa	cgtgggcctt	gcttcgcttt	tgagggccat	aagctcattg	60
	cccactgggt	tagaggctac	cttatcattg	tctcccgtga	ccggaagggt	tctcccaagt	120
	cagagttttac	cagcagggat	tcacagagct	ccgacaagca	gattctaaac	atctatgacc	180
	tgtgcaacaa	gttcatagcc	tatagcaccg	tctttgagga	tgtagtggtg	gtgcttgctg	240
40	agtggggctc	cctgtacgtg	ctgacgcggg	atgggcgggt	ccacgcactg	caggagaagg	300
	acacacagac	caaactggag	atgctgttta	agaagaacct	atttgagatg	gcgattaacc	360
	ttgccaagag	ccagcatctg	gacagtgtat	ggctggccca	gattttcatg	cagtatggag	420
	accatctcta	cagcaagggc	aaccacgatg	gggctgtcca	gcaatatatc	cgaaccattg	480
	gaaagttgga	gccatcctac	gtgatccgca	agttttctgga	tgcccagcgc	attcacaacc	540
45	tgactgccta	cctgcagacc	ctgcaccgac	aatccctggc	caatgccgac	cataccaccc	600
	tgctcctcaa	ctgctatacc	aagctcaagg	acagctcgaa	gctggaggag	ttcatcaaga	660
	aaaagagtga	gagtgaagtc	cactttgatg	tgagacagc	catcaaggtc	ctccggcagg	720
	ctggctacta	ctccatgcc	ctgtatctgg	cggagaacca	tgacatcat	gagtggtacc	780
	tgaagatcca	gctagaagac	attaagaatt	atcaggaagc	ccttcgatac	atcggcaagc	840
50	tgctttttga	gcaggcagag	agcaacatga	agcgtacgg	caagatcctc	atgcaccaca	900
	taccagagca	gacaactcag	ttgctgaagg	gactttgtac	tgattatcgg	cccagcctcg	960
	aaggccgcag	cgatagggag	gccccaggct	gcagggccaa	ctctgaggag	ttcatcccca	1020
	tctttgccaa	taaccgcga	gagctgaaag	ccttcctaga	gcacatgagt	gaagtgcagc	1080
	cagactcacc	ccaggggatc	tacgacacac	tccttgagct	gcgactgcag	aactgggccc	1140
55	acgagaagga	tccacaggtc	aaagagaagc	ttcacgcaga	ggccatttcc	ctgctgaaga	1200
	gtggctcgct	ctgcgacgtc	tttgacaagg	ccctggctct	gtgccagatg	cacgacttcc	1260
	aggatgggtg	cctttacctt	tatgagcagg	ggaagctgtt	ccagcagatc	atgcactacc	1320
	acatgcagca	cgagcagtac	cggcaggtca	tcagcgtgtg	tgagcgccat	ggggagcagg	1380
	acccctcctt	gtgggagcag	gccctcagct	acttcgctcg	caaggaggag	gactgcaagg	1440
	agtatgtggc	agctgtcctc	aagcatatcg	agaacaagaa	cctcatgcca	cctcttctag	1500
60	tggtgcagac	cctggcccac	aactccacag	ccacactctc	cgatcatcag	gactacctgg	1560
	tccaaaaact	acagaaacag	agccagcaga	ttgcacagga	tgagctgcgg	gtgcggcggt	1620
	accgagagga	gaccaccctg	atccgcagg	agatccaaga	gctcaaggcc	agtcctaaga	1680
	ttttccaaaa	gaccaagtgc	agcatctgta	acagtgcctt	ggagttgccc	tcagtccact	1740
	tcctgtgtgg	ccactccttc	caccaacact	gctttgagag	ttactcggaa	agtgatgctg	1800
65	actgcccac	ctgcctccct	gaaaaccgga	aggtcatgga	tatgatccgg	gccagggaac	1860
	agaaacgaga	tctccatgat	caattccagg	atcagctcaa	gtgctccaat	gacagctttt	1920

	ctgtgattgc	tgactacttt	ggcagagggtg	ttttcaacaa	attgactctg	ctgaccgacc	1980
	ctcccacagc	cagactgacc	tccagcctgg	aggctgggct	gcaacgcgac	ctactcatgc	2040
	actccaggag	gggcacttaa	gcagcctgga	ggaagatgtg	ggcaacagtg	gaggaccaag	2100
	agaacagaca	caatgggacc	tgggcgggcg	ttacacagaa	ggctggctga	catgcccagg	2160
5	gctccactct	catctaattgt	cacagccctc	acaagactaa	agcggaactt	tttcttttcc	2220
	ctggccttcc	ttaatttttaa	gtcaagcttg	gcaatccctt	cctctttaac	taggcagggtg	2280
	ttagaatcat	ttccagatta	atgggggggga	aggggaacct	caggcaaacc	tcctgaagtt	2340
	ttggaaaaaa	aagctgggtt	c				
10	<210> 21						
	<211> 179						
	<212> DNA						
	<213> Human						
15	<400> 21						
	aggtgtaga	tgctcttgaa	aaagaaactg	catctaagct	gtcagaaatg	gattctttta	60
	acaatcaact	aaaggaactg	agagaaacct	acaacacaca	gcagttagcc	cttgaacagc	120
	tttataagat	caacgtgaca	agttgaagga	aattgaaagg	aaaaaattag	aactaatgc	
20	<210> 22						
	<211> 905						
	<212> DNA						
	<213> Human						
25	<400> 22						
	tttttttttt	ttctttaacc	gtgtgggtctt	tatttcagtg	ccagtgttac	agatacaaca	60
	caaagtgtcc	agttagaagg	aattcaaacy	gaatgccaa	gtccaagcca	ggctcaagaa	120
30	ataaaaagg	aggtttggag	taatagataa	gatgactcca	atactcactc	ttcctaagg	180
	caaaggtact	tttgatacag	agtctgatct	ttgaaactgg	tgaactcctc	ttccaccat	240
	taccatagtt	caaacaggca	agttatgggc	ttaggagcac	tttaaaattt	gtgggtggaa	300
	taggggtcatt	aataactatg	aataatctct	ttagaagggtg	accattttgc	actttaaagg	360
	gaatcaattt	tgaaaatcat	ggagactatt	catgactaca	gctaaagaat	ggcgagaaag	420
35	gggagctgga	agagccttgg	aagtttctat	tacaaataga	gcaccatata	cttcattgcca	480
	aatctcaaca	aaagctcttt	ttaactccat	ctgtccagtg	tttacaataa	aactcgcaag	540
	gtctgaccag	ttcttggtta	caaacataca	tgtgtgtgtc	tgtgtgtata	cagcaatgca	600
	cagaaaaggc	taccaggagc	ctaatagcctc	tttcaaacat	tgggggaacc	agtagaaaaa	660
	ggcagggctc	cctaattgtcc	attattacat	ttccattccg	aatgccagat	gttaaaagtg	720
40	cctgaagatg	gtaaccagc	tagtgaggaa	taaaatcccc	accttgccca	gtccacagag	780
	aaacaacagt	agaaagaagg	ggcaactctt	tgctgcagag	acaaagttag	tgttttttcg	840
	ccatggattg	cagtcctctc	ctccagacca	gctgcttatt	tcctcagggg	cccagggaa	900
	gttga						
45	<210> 23						
	<211> 2134						
	<212> DNA						
	<213> Human						
50	<400> 23						
	ggctctctct	ttcttttttt	tttttccaaa	agtgttcttt	tatttctagt	aacatatatt	60
	gtataaatac	tctattttat	atgcacttcc	acaaaagcga	tataatttaa	aagttttttt	120
	cattagaaat	aaatgtataa	aaataaatat	gttattatag	gcattttatta	ctaactatag	180
55	tccttcttgg	aaggaacacc	caaaccaata	cttataaagt	acatgtaatt	tatagtaaca	240
	tattttacta	tatacatatg	gaaaaaatca	tattctcaca	gaagagctga	acagacattc	300
	accaggatac	gactgttgga	ccagctgctg	gagatggacc	tgctaccctc	cagcagcctc	360
	cccaccacaa	gacaagtgat	ctcaatgtcc	ccaaacctgt	gggacctgt	tctacacacc	420
	tcatttttgt	tccggcggtt	catcctcctt	gtgtgattgt	actgattttc	atgagacaca	480
60	agttacttct	ttacatccat	attcccaaag	cagggttaca	tggtaggaaa	gaaaggaagt	540
	tggaggtact	aagctcattg	tgtctcctct	agcttttacc	agcatctaata	gcttcaactgc	600
	tttttttcca	ttgtagactt	taatgcactt	gaataaatac	atggagttgt	tttttctca	660
	aaatgaatta	cacaaataaa	gactgagatg	gtccaaaaaa	ggaaagagga	agccatttgc	720
	gttattttcac	gttgctgagc	ctttctctca	tgttgaacaa	tctgaagttt	taattctcgg	780
65	tagaaataat	gtataaacat	tctctgaaac	catagcagcc	ataaacagtg	ctgggtcaaag	840
	atcctatttg	tactcctttc	tccccccatt	gttagtgagg	taaagtaaaa	caggctcttag	900

taaaatctca cttttctcct acttttcatt tcccaacccc catgatacta agtattttgat 960  
 aagtaccagg aaacaggggt tgtaatagtt ctaacttttt ttgacaattg ctttgttttt 1020  
 tctaaacttg taatagatgt aacaaaagaa ataataataa taatgcccg ggctttatta 1080  
 5 tgctatatca ctgctcagag gttaataatc ctcactaact atcctatcaa atttgcaact 1140  
 ggcagtttac tctgatgatt caactccttt tctatctacc ccataatcc caccttactg 1200  
 atacacctca ctgggttactg gcaagatacg ctggatccct ccagccttct tgctttccct 1260  
 gcaccagccc ttcctcactt tgcttgccc tcaaagctaa caccacttaa accacttaac 1320  
 tgcattctgc cattgtgcaa aagtctatga aatgtttagg tttctttaaa ggatcacagc 1380  
 10 tctcatgaga taacacccct ccatcatggg acagacactt caagcttctt tttttgtaac 1440  
 ccttcccaca ggtcttagaa catgatgacc actccccag ctgccactgg gggcagggat 1500  
 ggtctgcaca aggtctgggt ctggctggct tcaacttctt tgcacactcg gaagcaggct 1560  
 gtccattaat gtctcgcat tctaccagtc ttctctgcca acccaattca catgacttag 1620  
 aacattcgcc ccactcttca atgacccatg ctgaaaaagt ggggatagca ttgaaagatt 1680  
 ccttcttctt ctttacgaag taggtgtatt taattttagg tcgaagggca ttgccacag 1740  
 15 taagaacctg gatggtcaag ggctctttga gagggctaaa gctgcgaatt ctttccaatg 1800  
 ccgcagagga gccgctgtac ctcaagacaa cacttttgta cataatgtct tgctctaagg 1860  
 tggacaaagt gtagtcacca ttaagaatat atgtgccatc agcagctttg atggcaagaa 1920  
 agctgccatt gttcctggat cccctctggg tccgctgttt cacttcgatg ttggtggctc 1980  
 cagttggaat tgtgatgata tcatgatatc caggttttgc actagtaact gatcctgata 2040  
 20 tttttttaca agtagatcca tttccccgc aaacaccaca tttatcaaac ttctttttg 2100  
 agtctatgat gcgatcaca ccagctttta caca  
  
 <210> 24  
 <211> 1626  
 25 <212> DNA  
 <213> Human  
  
 <400> 24  
  
 30 ggacaatttc tagaatctat agtagtatca ggatatattt tgctttaaaa tatattttgg 60  
 ttattttgaa tacagacatt ggctccaaat ttcatcttt gcacaatagt atgacttttc 120  
 actagaactt ctcaacattt ggaactttt caaatatgag catcatatgt gtttaaggctg 180  
 tatcatttaa tgctatgaga tacattgttt tctccctatg ccaaacaggt gaacaaacgt 240  
 35 agttgttttt tactgatact aaatgttggc tacctgtgat tttatagtat gcacatgtca 300  
 gaaaaaggca agacaaatgg cctctgttac tgaatacttc ggcaaactta ttgggtcttc 360  
 attttctgac agacaggatt tgactcaata ttgttagagc ttgcgtagaa tggattacat 420  
 ggtagtgatg cactggtaga aatggttttt agttattgac tcagaattca tctcaggatg 480  
 aatcttttat gtctttttat tgtaagcata tctgaattta ctttataaag atggtttttag 540  
 aaagctttgt ctaaaaattt ggctaggaa tggtaacttc attttcagtt gccaaagggt 600  
 40 agaaaaataa tatgtgtgtt gttatgttta tgtaacata ttattaggtta ctatctatga 660  
 atgtatttaa atatttttca tattctgtga caagcattta taatttgcaa caagtggagt 720  
 ccatttagcc cagtgggaaa gtcttggaac tcaggttacc cttgaaggat atgctggcag 780  
 ccatctcttt gatctgtgct taaactgtaa tttatagacc agctaaatcc ctaacttgga 840  
 45 tctggaatgc attagttatg cctgtacca ttcccagaat ttcaggggca tctgtgggtt 900  
 ggtctagtga ttgaaaacac aagaacagag agatccagct gaaaaagagt gatcctcaat 960  
 atcctaacta actggctctc aactcaagca gaggttcttc actctggcac tgtgatcatg 1020  
 aaacttagta gaggggattg tgtgtatttt atacaaattt aatacaatgt cttacattga 1080  
 taaaattctt aaagagcaaa actgcatttt atttctgcat ccacattcca atcatattag 1140  
 50 aactaagata tttatctatg aagatataaa tgggtgcagag agactttcat ctgtggattg 1200  
 cgttgtttct taggggttct agcactgatg cctgcacaag catgtgatat gtgaaataaa 1260  
 atggattctt ctatagctaa atgagttccc tctggggaga gttctggtac tgcaatcaca 1320  
 atgccagatg gtgtttatgg gctatttggt taagtaagtg gtaagatgct atgaagtaag 1380  
 tgtgtttgtt ttcatcttat ggaaactctt gatgcatgtg cttttgtatg gaataaattt 1440  
 55 tgggtgcaata tgatgtcatt caactttgca ttgaattgaa ttttggttgt atttatatgt 1500  
 attatacctg tcacgcttct agttgcttca accattttat aaccattttt gtacatatat 1560  
 tacttgaaaa tatttttaaat ggaaatttaa ataaacattt gatagtttac ataataaaaa 1620  
 aaaaaa  
  
 <210> 25  
 60 <211> 1420  
 <212> DNA  
 <213> Human  
  
 <400> 25  
  
 65 gttcagcatt gtttctgctt ctgaaatctg tatagtacac tggtttgtaa tcattatgtc 60





	ggtgaactca	gtgcattggg	ccaatgggtc	gacacaggct	ctgccagcca	caaccatcct	60
	gctgcttctg	acggtttggc	tgctgggtgg	ctttcccctc	actgtcattg	gaggcatctt	120
	tgggaagaac	aacgccagcc	cctttgatgc	accctgtcgc	accaagaaca	tcgcccggga	180
5	gattccaccc	cagccctggt	acaagtctac	tgatcatccac	atgactgttg	gaggcttcct	240
	gccttttcagt	gccatctctg	tggagctgta	ctacatcttt	gccacagtat	ggggtcggga	300
	gcagtacact	ttgtacggca	tectcttctt	tgtcttcgcc	atcctgctga	gtgtgggggc	360
	ttgcatctcc	attgactca	cctacttcca	gttgtctggg	gaggattacc	gctgggtggg	420
	gcgatctgtg	ctgagtgttg	gctccaccgg	cctcttcctc	ttcctctact	cagttttcta	480
10	ttatgcccgg	cgctccaaca	tgtctggggc	agtacagaca	gtagagtctt	tcggctactc	540
	cttactcact	ggttatgtct	tcttctcat	gctgggcacc	atctcctttt	tttcttccct	600
	aaagtctatc	cggatatact	atgttaacct	caagatggac	tgagtctctg	atggcagaac	660
	tattgctgtt	ctctcccttt	cttcatgccc	tgttgaactc	tcctaccagc	ttctctctcg	720
	attgactgaa	ttgtgtgatg	gcattgttgc	cttccctttt	tccctttggg	cattccttcc	780
15	ccagagaggg	cctggaaatt	ataaatctct	atcacataag	gattatata	ttgaactttt	840
	taagttgcct	ttagttttgg	tctgattttt	tctttttaca	attacccaaa	taaaatttat	900
	taagaaaaag	aaaaaaaaaa	aaaaaaaaaa				
	<210>	29					
20	<211>	1775					
	<212>	DNA					
	<213>	Human					
	<400>	29					
25	gaacgtgatg	ggaacttttg	gaggatgtct	gagaaaaatgt	ccgaagggat	tttggccaac	60
	accagaaaaac	gccaatgtcc	taggaattcc	ctcccaaaaat	gcttcccaaa	aaattactca	120
	ttgacaattc	aaattgcact	tggtggcg	cagcccgggc	ggccttcagt	ccgtgtgggg	180
	cgcccgcggtg	gccttctcct	cgtaggactc	cccaaaactcg	ttcactctgc	gtttatccac	240
30	aggataaaagc	caccgctggt	acaggtagac	cagaaacacc	acgtcgtccc	ggaagcaggc	300
	cagccggtga	gacgtgggca	tggtgatgat	gaaggcaaaag	acgtcatcaa	tgaaggtgtt	360
	gaaagcccttg	taggtgaagg	ccttccaggg	cagatgtgcc	actgacttca	actttagatt	420
	cacaaagagc	tggggcagca	tgaagaggaa	accaaaggca	tagaccccg	tgacgaagct	480
	gttgattaac	caggagtacc	agctcttata	ttgatattc	aggagtgaat	agacagcacc	540
35	cccgacacag	agagggtaca	gcaggatga	caagtacttc	atggcctgag	tatcgtactc	600
	ctcgggttttc	ctctcagatt	cgtctgaagt	gccaaactga	aattcgggca	tcaggcctct	660
	ccaaaaaata	gtcatcttca	atgccttctt	cactttccac	agctcaatgg	cggctccaac	720
	accgcgcggg	accagcacca	gcaggctcgt	ctgctcgtcc	agcaggaaca	gaaagatgac	780
	cacggtgctg	aagcagcgcc	agagcactgc	cttgggtggac	atgccgatca	tgctcttctt	840
40	cttcttccag	aaactgatgt	cattttttaa	ggccaggaaa	tcaaagagaa	gatggaacgc	900
	tgcgacaaaag	aaggtcagcg	ccaggaagta	taagttggta	tctacaaaaa	ttcctttcac	960
	ctcatcagca	tctttctctg	aaaaccggaa	ctgctgcagg	gagtacacgg	cgctcctgcat	1020
	gtggatccag	aagcgcagcc	gccccagtg	gaccttgtcg	taggacacgg	tgagggggcag	1080
	ctcgggtggtg	gagcggttta	tgaccatcag	gtccttcacg	cggttgctga	gctgggtcgat	1140
45	gaacaggatg	ggcaggtaat	gcacggtttt	ccccagctgg	atcatcttca	tgtaccgatg	1200
	cacatcgcca	ggcagggagg	accggtcaaa	gacaaagtgg	tccgccatca	cgttcagcgc	1260
	cagccgcgggt	cgccagtggg	acactggctc	atccagggca	ctcgtcggct	tcttctccgc	1320
	ctcgatctgc	tgtgtatcag	actccccgg	gagcaggttg	atttcttctg	gcttggggac	1380
	catgtagggtg	gtcagaggac	tgaccagggtg	cacttgcttc	ccgtcgtgcc	acggcaggac	1440
50	cccagcgtga	tggaggaaga	tgtaggcata	cagcgtccca	ttgtttctcg	ttttcttttg	1500
	tacagaaaca	ttaactgtcc	tttcaaattt	ggactccaca	tcaaagtctt	ccacattcaa	1560
	gaccaggtcg	atgttgttct	cagcacccag	gtgggacctc	gtcgtgggtg	acacgtcag	1620
	ctgcagcttg	ggccgcggcg	ccaggtaggg	ctggatgcag	ttggcgtcgc	cggagcacgg	1680
	gcggtgtag	acgatgccgt	acatgacca	gcaggtgtgc	accacgtaga	ccacgaacac	1740
55	gcccaccacc	aagctggtga	aggagctcgg	gccc			
	<210>	30					
	<211>	1546					
	<212>	DNA					
60	<213>	Human					
	<400>	30					
	aaaataagta	ggaatgggca	gtgggtattc	acattcacta	caccttttcc	atttgcta	60
65	aaggccctgc	caggctggga	gggaattgtc	cctgcctgct	tctggagaaa	gaagatattg	120

	acaccatcta	cgggcacccat	ggaactgctt	caagtgaacca	ttctttttct	tctgcccagt	180
	atgtgcagca	gtaacagcac	aggtgtttta	gaggcagcta	ataattcact	tggtgttact	240
	acaacaaaaac	catctataac	aacaccaaac	acagaatcat	tacagaaaaa	tggtgtcaca	300
5	ccaacaactg	gaacaactcc	taaaggaaca	atcaccaatg	aattacttaa	aatgtctctg	360
	atgtcaacag	ctactttttt	aacaagtaaa	gatgaaggat	tgaaagccac	aaccactgat	420
	gtcaggaaga	atgactccat	catttcaaac	gtaacagtaa	caagtgttac	acttccaaat	480
	gctgtttcaa	cattacaaaag	ttccaaaccc	aagactgaaa	ctcagagtcc	aattaaaaca	540
	acagaaatac	caggtagtgt	tctacaacca	gatgcatcac	cttctaaaaac	tggtacatta	600
	acctcaatac	cagttacaat	tccagaaaaac	acctcacagt	ctcaagtaat	aggcactgag	660
10	ggtggaaaaa	atgcaagcac	ttcagcaacc	agccggtctt	attccagtat	tattttgccg	720
	gtgggttattg	ctttgattgt	aataacactt	tcagtatttg	ttctggtggg	tttgtaccga	780
	atgtgctgga	aggcagatcc	gggcacacca	gaaaatggaa	atgatcaacc	tcagtctgat	840
	aaagagagcg	tgaagcttct	taccgttaag	acaatttctc	atgagtctgy	tgagcactct	900
	gcacaaggaa	aaaccaagaa	ctgacagctt	gaggaattct	ctccacacct	aggcaataat	960
15	tacgcttaat	cttcagcttc	tatgcaccaa	gcgtggaaaa	ggagaaaagtc	ctgcagaatc	1020
	aatcccgact	tccatacctg	ctgctggact	gtaccagacg	tctgtcccag	taaagtgatg	1080
	tccagctgac	atgcaataat	ttgatggaa	caaaaagaac	cccggggctc	tcctgttctc	1140
	tcacatttaa	aaattccatt	actccattta	caggagcggt	cctaggaaaa	ggaatttttag	1200
	gaggagaatt	tgtgagcagt	gaatctgaca	gcccaggagg	tggtgctcgt	gataggcatg	1260
20	acttttcctta	atgttttaaag	ttttccgggc	caagaatttt	tatccatgaa	gactttccta	1320
	cttttctcgg	tggttcttata	ttacctactg	ttagtattta	ttgtttacca	ctatgttaat	1380
	gcagggaaaa	gttgacagtg	tattattaaa	tattaggtag	aaatcatacc	atgctacttt	1440
	gtacatataa	gtattttatt	cctgctttcg	tgttactttt	aataaataac	tactgtactc	1500
25	aatactctaa	aaatactata	acatgactgt	gaaaatggca	aaaaaa		
	<210>	31					
	<211>	750					
	<212>	DNA					
	<213>	Human					
30	<400>	31					
	cacttgggca	ccccattttt	ctaaaaaat	ggaaatctgg	agggcaaaaa	aggtgtgctg	60
	aaggggaagtg	cctctgatgg	cccaaaaaac	ttcttccaaa	ctagtgtagg	aatggaatgg	120
35	atagcaaatg	gatccttttt	ggcctccttt	ggagcatgcc	ttccctatct	tatccttgge	180
	ccactaaag	cagaacgtta	cggatatttc	tggttttgcc	attggatgcc	tatctggcca	240
	aacagccttt	ccctaattgg	aaaatgcagt	cctgttttaa	acctttgatt	tacgactact	300
	tgtacatgct	tgctcattac	aattttgaca	ttttttacat	agtgaagacc	ccaacatat	360
	cagtgaaca	tgacaagatc	ataaagaaca	gtatcatatt	attatttagt	cgcttttaca	420
40	gtggcaagcc	aattttgaaa	tatctcattt	aaaactcaga	cccaattcac	tgagtatac	480
	ttttaatagc	ttcctcagca	cactatttcc	catgcattaa	atatgataaa	ataatctatc	540
	actgccatc	ggtcttgtaa	aaaggaagtc	tgaatacaga	gccacaaca	ctaaaattgt	600
	ttttctagct	acaaagtata	gcacatcaa	cacagacacg	atttggaactc	cctgacaggt	660
	ggattggaaa	acggtgttta	aagagaagag	aacattttta	cataaatgtc	attaagaatc	720
45	ccaaaggcct	tatttgtcac	caccgtcccg				
	<210>	32					
	<211>	1620					
	<212>	DNA					
50	<213>	Human					
	<400>	32					
	gcaattcccc	cctcccacta	aacgactccc	agtaattatg	tttacaaccc	attggatgca	60
55	gtgcagccat	tcataagaac	cttggtgccc	cagaaaaatc	tgctcctttt	ggtaccaaac	120
	ctgaggtctt	ttggaagata	atgtagaaaa	ccactaccta	ttgaaggcct	gttttggtcta	180
	atctgtgcaa	actctgatga	tacctgcctt	atgtggattc	ttttccacac	tgctttcatt	240
	tttaagtata	aagacttaga	aaactagaat	aatgctttta	caaataatta	aaagtatgtg	300
	atgttctggg	ttttttcctt	cttttttagaa	ccccgcctcc	atttaaaaaa	ttaaaaaaa	360
60	aaaaaaaact	tttaacattt	aaaaaataaa	aattaacaaa	atttcaactta	ttccaggaca	420
	cgctggcact	tgactcaat	gaaaagggca	cctaaagaaa	ataaggctga	ctgaatgttt	480
	tccataattt	tcacacaata	acagtcctct	tctatccagc	ttgccttcca	tttatctcta	540
	gggttagctt	ttcaggcaac	atccttggtc	attgcccaga	aagtacctga	gctatcagtg	600
	attggaatgg	cacaggaaac	cgaatcacat	gggtgccctc	cccttggttt	tcaagtatct	660
65	tggaagtgtg	cacaaaaatt	aggtcatgcc	ttcagtgctt	tgttctttta	acctaccctt	720
	tgacaatcag	gtgctaataga	ttgtatacta	ttaaaaccag	cacataagta	ttgtaaatgt	780

	gtgttcctcc	taggttgga	gaaatgtctt	tccttctatc	tgggtcctgt	taaagcgggt	840
	gtcagttgtg	tcttttcacc	tcgatttgtg	aattaataga	attgggggga	gaggaaatga	900
	tgatgtcaat	taagtttcag	gtttggcatg	atcatcattc	tcgatgatat	tctcactttg	960
5	tcgcaaatct	gcccttatcg	taagaacaag	tttcagaatt	ttccctccac	tatacgactc	1020
	cagtattatg	tttacaatcc	attggatgag	tgcagcatta	taagaccttg	gtgcccagaa	1080
	aaatctgtcc	tttttggtac	caaacctgag	gtcttttgga	agataatgta	gaaaaccact	1140
	acctattgaa	ggcctgtttt	ggctaactctg	tgcaaaactct	gatgatacct	gcttatgtgg	1200
	attctttttc	acactgcttt	catttttaag	tataaagact	tagaaaacta	gaataatgct	1260
10	tttacaata	attaaaagta	tgtgatgttc	tgggtttttt	ccttcttttt	agaacctgt	1320
	atttaacaa	gccttctttt	taagtcttgt	ttgaaattta	agtctcagat	cttctggata	1380
	ccaaatcaaa	aacccaacgc	gtaaaacagg	gcagtatttg	tgttccta	tttaaaaagc	1440
	tttatgtata	ctctataaat	atagatgcat	aaacaacact	tccccttgag	tagcacatca	1500
	acatacagca	ttgtacatta	caatgaaaat	gtgtaactta	agggatttat	atatataaat	1560
15	acatatatac	ctttgtaacc	tttatactgt	aaataaaaaa	gttgctttag	tcaaaaaaaa	1620
	<210> 33						
	<211> 2968						
	<212> DNA						
	<213> Human						
20	<400> 33						
	gaaaaagtag	aaggaaacac	agttcatata	gaagtaaaag	aaaaccctga	agaggaggag	60
25	gaggaggaag	aagaggaaga	agaagatgaa	gaaagtgaag	aggaggagga	agaggaggga	120
	gaaagtgaag	gcagtgaag	tgatgaggaa	gatgaaaagg	tgtcagatga	gaaggattca	180
	gggaagacat	tagataaaaa	gccaagtaaa	gaaatgagct	cagattctga	atatgactct	240
	gatgatgac	ggactaaaga	agaaagggct	tatgacaaag	caaaacggag	gattgagaaa	300
	cggcgacttg	aacatagtaa	aatgtaaac	accgaaaagc	taagagcccc	tattatctgc	360
30	gtacttgggc	atgtggacac	agggaagaca	aaaattctag	ataagctccg	tcacacacat	420
	gtacaagatg	gtgaagcagg	tggatcacaca	caacaaattg	gggccaccaa	tgttcctctt	480
	gaagctatta	atgaacagac	taagatgatt	aaaaattttg	atagagagaa	tgtacggatt	540
	ccaggaatgc	taattattga	tactcctggg	catgaatctt	tcagtaatct	gagaaataga	600
	ggaagctctc	tttgtgacat	tgccattttt	gttgttgata	ttatgcatgg	tttggagccc	660
35	cagacaattg	agtctatcaa	ccttctcaaa	tctaaaaaat	gtcccttcat	tggtgcactc	720
	aataagattg	ataggttata	tgattggaag	aagagtcctg	actctgatgt	ggctgctact	780
	ttaaagaagc	agaaaaagaa	tacaaaagat	gaatttgagg	agcgagcaaa	ggctattatt	840
	gtagaatttg	cacagcagg	tttgaatgct	gctttgtttt	atgagaataa	agatccccgc	900
	acttttgtgt	cttttggtacc	tacctctgca	catactgggtg	atggcatggg	aagtctgatc	960
40	taccttcttg	tagagttaac	tcagaccatg	ttgagcaaga	gacttgcaca	ctgtgaagag	1020
	ctgagagcac	aggtgatgga	ggttaaagct	ctcccgggga	tgggcaccac	tatagatgtc	1080
	atcttgatca	atgggcgttt	gaaggaagga	gatacaatca	ttgttcctgg	agtagaaggg	1140
	cccattgtaa	ctcagattcg	aggcctcctg	ttacctctc	ctatgaagga	attacgagtg	1200
	aagaaccagt	atgaaaagca	taagaagta	gaagcagctc	agggggtaaa	gattcttgga	1260
45	aaagaccctgg	agaaaacatt	ggctggttta	cccctccttg	tggcttataa	agaagatgaa	1320
	atccctgttc	ttaaagatga	attgatccat	gtgttaaagc	agacactaaa	tgctatcaaa	1380
	ttagaagaaa	aaggagtcta	tgtccaggca	tctacactgg	gttcttttga	agctctactg	1440
	gaatttctga	aaacatcaga	agtgccttat	gcaggaatta	acattggccc	agtgcataaa	1500
	aaagatgtta	tgaaggcttc	agtgatgttg	gaacatgacc	ctcagtatgc	agtaattttg	1560
50	gccttcgatg	tgagaattga	acgagatgca	caagaaatgg	ctgatagttt	aggagttaga	1620
	attttttagtg	cagaaattat	ttatcattta	tttgatgcct	ttacaaaata	tagacaagac	1680
	tacaagaaac	agaaacaaga	agaatttaag	cacatagcag	tatttccctg	caagataaaa	1740
	atcctccctc	agtacatttt	taattctcga	gatccgatag	tgatgggggt	gacgggtgga	1800
	gcaggtcagg	tgaacagg	gacacccatg	tgtgtcccaa	gcaaaaattt	tgttgacatc	1860
55	ggaatagtaa	caagtattga	aataaacatt	aaacaagtgg	atgttgcaaa	aaaaggacaa	1920
	gaagtttgg	taaaaataga	acctatccct	ggtgagtcac	ccaaaatgtt	tggaagacat	1980
	tttgaagcta	cagatattct	tgtagtaag	atcagccggc	agtcattga	tgcaactcaa	2040
	gactgggtca	gagatgaaat	gcagaagagt	gactggcagc	ttattgtgga	gctgaagaaa	2100
	gtatttgaaa	tcatctaatt	ttttcacatg	gagcaggaac	tggagtaaat	gcaatactgt	2160
60	gttgtaatat	cccaacaaaa	atcagacaaa	aatggaaca	gacgtatttg	gacactgatg	2220
	gacttaagta	tggaaggaag	aaaaaatagg	gtataaaaatg	ttttccatga	gaaaccaaga	2280
	aacttacact	gggttgacag	tggtcagtta	catgtcccca	cagttccaat	gtgcctgttc	2340
	actcacctct	cccttcccca	acccttctct	acttggtctg	tgtttttaag	tttgcccttc	2400
	cccaatttgg	gatttttatt	acagatctaa	agctctttcg	atttttatact	gattaaatca	2460
65	gtactgtcagt	attttgattaa	aaaaaaaaaa	gcagattttg	tgattctttg	gacttttttg	2520
	acgtaagaaa	tacttcttta	tttatgcata	ttcttcccaa	agtgattttt	ccagcattct	2580
	tctgccatat	gccttttaggg	cttttataaa	atagaaaaat	aggcattctg	atatttcttt	2640

	agctgctttg	tgtgaaacca	tggtgtaaaa	gcacagctgg	ctgcttttta	ctgcttgtgt	2700
	agtcacgagt	ccattgtaat	catcacaatt	ctaaaccaa	ctaccaataa	agaaaacaga	2760
	catccaccag	taagcaagct	ctgttaggct	tccatggtta	gtggtagctt	ctctcccaca	2820
5	agttgtcctc	ctaggacaag	gaattatctt	aacaaactaa	actatccatc	acactacctt	2880
	ggtatgccag	cacctgggta	acagtaggag	attttatata	ttaatctgat	ctgtttaatc	2940
	tgatcgggtt	agtagagatt	ttatacat				
	<210>	34					
	<211>	6011					
10	<212>	DNA					
	<213>	Human					
	<400>	34					
15							
	acggggcgcc	ggacgacccg	cacatcttat	cctccacgcc	ccactcgcac	tcggagcggg	60
20	accgccccgg	actccccctc	gggcccggcca	ctcgaggagt	gaggagagag	gccgcccggc	120
	cggcttgagc	cgagcgcagc	accccccgcg	ccccgcgcca	gaagtgttgg	tgaaccgggc	180
	tgccgggaga	aacttttttc	ttttttcccc	ctctcccggg	agagtctctg	gaggaggagg	240
	ggaactcccc	cggcccaagg	ctcgtgggct	cggggtcgcg	cggccgcaga	aggggccccg	300
	tccgcccccg	aggggaggcg	cccccgggga	cccgagaggg	gggtgaggac	cgcgggctgc	360
	tggtgcggcg	gcggcagcgt	gtgcccccg	caggggaggc	gccgccccgc	tcccggcccc	420
25	gctgcgagga	ggaggcgggc	gcggcgcagg	aggatgtact	tggtggcggg	ggacaggggg	480
	ttggccggct	gcgggcacct	cctggtctcg	ctgctggggc	tgctgctgct	gccggcgcg	540
	tccggcacc	gggcgctgg	ctgcctgccc	tgtgacgagt	ccaagtgcga	ggagcccagg	600
	aaccgccccg	ggagcatcgt	gcagggcgct	tgccgctgct	gctacacgtg	cgcagccag	660
	gggaacgaga	gctgcggcgg	caccttcggg	atttacggaa	cctgcgaccg	gggctgctg	720
30	tgtgtcatcc	gcccccgct	caatggcgac	tccctcaccg	agtacgaagc	ggcggttgc	780
	gaagatgaga	actggactga	tgaccaactg	cttgggttta	aaccatgcaa	tgaaaacctt	840
	attgctggct	gcaatataat	caatgggaaa	tgtgaatgta	acaccattcg	aacctgcagc	900
	aatccctttg	agttttcaag	tcaggatatg	tgcccttcag	ctttaaagag	aattgaagaa	960
	gagaagccag	attgctccaa	ggcccgtgt	gaagtccagt	tctctccacg	ttgtcctgaa	1020
35	gattctgttc	tgatcgaggg	ttatgctcct	cctggggagt	gctgtccctt	accagccgc	1080
	tgcgtgtgca	accccgccag	ctgtctgcgc	aaagtctgcc	agccgggaaa	cctgaacata	1140
	ctagtgtcaa	aagcctcagg	gaagccggga	gagtgtgtg	acctctatga	gtgcaaacca	1200
	gttttcggcg	tggactgcag	gactgtggaa	tgccctactg	ttcagcagac	cgcgtgtccc	1260
	ccggacagct	atgaaactca	agtcagacta	actgcagatg	gttgctgtac	tttgccaaca	1320
40	agatgcgagt	gtctctctgg	cttatgtggt	ttccccgtgt	gtgaggtggg	atccactccc	1380
	cgcatagtct	ctcgtggcga	tgggacacct	ggaaaagtgt	gtgatgtctt	tgaatgtggt	1440
	aatgatacaa	atgccagcctg	cgtatttaac	aagtgtggaat	attatgatgg	agacatgttt	1500
	cgaatggaca	actgtcgggt	ctgtcgatgc	caagggggcg	ttgccatctg	cttcaccgcc	1560
45	cagtgtggtg	agataaactg	cgagaggtac	tacgtgcccg	aaggagagtg	ctgcccagtg	1620
	tgtgaagatc	cagtgtatcc	ttttaataat	cccgtgtggt	gctatgccaa	tgccctgatc	1680
	cttgcccacg	gagaccgggtg	gcgggaagac	gactgcacat	tctgccagtg	cgtcaacggg	1740
	gaacgccact	gcgttgcgac	cgtctgcgga	cagacctgca	caaaccctgt	gaaagtgcct	1800
	ggggagtgtt	gccctgtgtg	cgaagaacca	accatcatca	cagttgatcc	acctgcatgt	1860
50	ggggagtgtt	caaactgcac	tctgacacgg	aaggactgca	ttaatgtgtt	caaacgcgat	1920
	cacaatggtt	gtcggacctg	tcagtgcata	aacaccagg	aactatgttc	agaacgtaaa	1980
	caaggctgca	ccttgaactg	tcccttcggg	ttccttactg	atgcccataa	ctgtgagatc	2040
	tgtgagtgcc	gcccagggcc	caagaagtgc	agaccataa	tctgtgacaa	gtattgtcca	2100
	cttgattgct	tgaagaataa	gcacggctgt	gacatctgtc	gctgtaagaa	atgtccagag	2160
	ctctcatgca	gtaagatctg	ccccttgggt	ttccagcagg	acagtcacgg	ctgtcttatc	2220
55	tgcaagtgca	gagaggcctc	tgcttcagct	gggccaccca	tcctgtcggg	cacttgtctc	2280
	accgtggatg	gtcatcatca	taaaaatgag	gagagctggc	acgatgggtg	ccgggaatgc	2340
	tactgtctca	atggacggga	aatgtgtgcc	ctgatcacct	gcccggtgcc	tgccgtgtgg	2400
	aacccaccca	ttcacccctg	acagtgtctg	ccatcatgtg	cagatgactt	tgtggtgcag	2460
	aagccagagc	tcagtactcc	ctccatttgc	cacgcccctg	gaggagaata	ctttgtggaa	2520
60	ggagaaacgt	ggaacattga	ctcctgtact	cagtgcacct	gccacagcgg	acgggtgtgt	2580
	tgtgagacag	aggtgtgccc	accgtgtctc	cgcagaaacc	cctcacgcac	ccaggattcc	2640
	tgtgcccac	atgtgtacaga	tcaacctttt	cggccttcct	tgtcccgcga	taacagcgta	2700
	cctaattact	gcaaaaaatga	tgaaggggat	atattcctgg	cagctgagtc	ctggaagcct	2760
	gacgtttgta	ccagctgcat	ctgcattgat	agcgtaatga	gctgtttctc	tgagtcctgc	2820
65	ccttctgtat	cctgtgaaag	acctgtcttg	agaaaaggcc	agtgtgttcc	ctactgcata	2880
	aaagacacaa	ttccaaagaa	ggtggtgtgc	cacttcagtg	ggaaggccta	tgccgacgag	2940

	gagcgggtggg	accttgacag	ctgcacccac	tgctactgcc	tgcagggcca	gaccctctgc	3000
	tcgaccgtca	gctgcccccc	tctgcccgtg	gttgagccca	tcaacgtgga	aggaagttgc	3060
	tgcccaatgt	gtccagaaat	gtatgtccca	gaaccaacca	atatacccat	tgagaagaca	3120
5	aaccatcgag	gagaggttga	cctggagggt	cccctgtggc	ccacgcctag	tgaaaatgat	3180
	atcgtccatc	tccctagaga	tatgggtcac	ctccaggtag	attacagaga	taacaggctg	3240
	cacccaagtg	aagattcttc	actggactcc	attgcctcag	ttgtgggtcc	cataattata	3300
	tgctctctta	ttataatagc	attcctattc	atcaatcaga	agaaacagtg	gataccactg	3360
	ctttgctggt	atcgaacacc	aactaagcct	tcttccttaa	ataatcagct	agtatctgtg	3420
	gactgcaaga	aaggaaccag	agtccagggt	gacagttccc	agagaatgct	aagaattgca	3480
10	gaaccagatg	caagattcag	tggcttctac	agcatgcaaa	aacagaacca	tctacaggca	3540
	gacaatttct	accaaacagt	gtgaagaaag	gcaactagga	tgagggttca	aaagacggaa	3600
	gacgactaaa	tctgctctaa	aaagtaaact	agaattttgt	cacttgctta	gtggattgta	3660
	ttggattgtg	acttgatgta	cagcgctaag	accttactgg	gatgggctct	gtctacagca	3720
	atgtgcagaa	caagcattcc	cacttttctc	caagataact	gaccaagtgt	tttcttagaa	3780
15	ccaaagtttt	taaagtgtgt	aagatatatt	tgcctgtaag	atagctgtag	agataatttg	3840
	ggtagggaga	gtgagtttgg	atggggaaag	gggtgggagg	gtgggtgttg	gaagaaaaat	3900
	tggtcagctt	ggctcgggga	gaaacctggg	aacataaaaag	cagttcagtg	gcccagaggt	3960
	tatttttttc	ctattgctct	gaagactgca	ctgggttgctg	caaagctcag	gcctgaatga	4020
	gcaggaaaca	aaaaaggcct	tgcgacccag	ctgccataac	caccttagaa	ctaccagacg	4080
20	agcacatcag	aaccttttga	cagccatccc	aggctctaaag	ccacaagttt	ctttctata	4140
	cagtcacaac	tgacgttagc	agttaggaag	ccagagaaat	gcgatagcgg	catttctcta	4200
	aagcgggtta	ttaaggatat	atacagttac	actttttgct	gcttttattt	tcttccaagc	4260
	caatcaatca	gccagttcct	agcagagtca	gcacatgaac	aagatctaag	tcatttcttg	4320
	atgtgagcac	tggagctttt	tttttttaca	acgtgacagg	aagaggaggg	agagggtgac	4380
25	gaacaccagg	catttccagg	ggctatatatt	cactgtttgt	tgtgtctttg	ttctgttata	4440
	ttgtttggtg	ttcatagttt	ttgttgaagc	tctagcttaa	gaagaaactt	tttttaaaaa	4500
	gactgttttg	ggattctttt	tccttattat	atactgatcc	tacaaaaatg	aaactacttc	4560
	attttaattg	tatattattc	aagcaccttt	gttgaagctc	aaaaaaaaatg	atgcctcttt	4620
	aaactttagc	aattatagga	gtattttatgt	aactatctta	tgcttcaaaa	aacaaaagta	4680
30	tttgtgtgca	tgtgtatata	atatatatat	atacatatat	atttatacac	atacaattta	4740
	tgttttccctg	ttgaatgtat	ttttatgaga	ttttaaccag	aacaaaaggca	gataaacagg	4800
	cattccatag	cagtgccttt	gatcacttac	aaattttttg	aataacacaa	aatctcattc	4860
	tacctgcagt	ttaattggaa	agatgtgtgt	gtgagagtat	gtatgtgtgt	gtgtgtgtgt	4920
	gtgtgtgcgc	gcgcacgcac	gccttgagca	gtcagcattg	cacctgctat	ggagaagggg	4980
35	attcctttat	taaaatcttc	ctcatttgga	tttgctttca	gttgggtttc	aatttgctca	5040
	ctggccagag	acattgatgg	cagttcttat	ctgcatcact	aatcagctcc	tggatttttt	5100
	tttttttttt	tcaaacaatg	gtttgaaaca	actactggaa	tattgtccac	aataagctgg	5160
	aagtttggtg	tagtatgcct	caaataaac	tgactgtata	ctatagtggg	aacttttcaa	5220
	acagccctta	gcactttttat	actaattaac	ccatttgtgc	attgagtttt	cttttaaaaa	5280
40	tgcttgttgt	gaaagacaca	gatacccagt	atgcttaacg	tgaaaagaaa	atgtgttctg	5340
	ttttgtaaag	gaactttcaa	gtattgttgt	aaataacttg	acagagggtg	ctgaacttta	5400
	aaaaaaatta	atattattatt	ataatgacct	aattttattaa	tctgaagatt	aaccattttt	5460
	ttgtcttaga	atatcaaaaa	gaaaaagaaa	aagggtgttct	agctgtttgc	atcaaaaggaa	5520
	aaaaagattt	attatcaagg	ggcaatattt	ttatcttttc	caaaaataaat	ttgttaatga	5580
45	tacattacaa	aaatagattg	acatcagcct	gattagtata	aattttgttg	gtaattaatc	5640
	catttctggc	ataaaaagtc	tttatcaaaa	aaaattgtag	atgcttgctt	tttgtttttt	5700
	caatcatggc	catattatga	aaatactaac	aggatatagg	acaagggtga	aattttttta	5760
	ttattatttt	aaagatatga	tttatcctga	gtgctgtatc	tattactctt	ttactttggt	5820
	tcctgttgtg	ctcttgtaaa	agaaaaatat	aatttcctga	agaataaaaat	agatatatgg	5880
50	cacttgaggt	gcacatagat	tctacagttt	gtttttgttt	tcttcaaaaa	agctgtaaga	5940
	gaattatctg	caacttgatt	cttggcagga	aataaacatt	ttgagttgaa	atcaaaaaaa	6000
	aaaaaaaaaa	a					
55	<210>	34a					
	<211>	1036					
	<212>	DNA					
	<213>	Human					
60	<400>	34a					
	mylvagdrgl	agcghllvsl	lgllllpars	gtralvcclpc	deskceepn	rpgsivqgvc	60
	gccytcasgg	nescgggtfgi	ygtcdrglrc	virpplngds	lteyeagvce	denwtdddql	120
65	gfkpcnenli	agcniingkc	ecntirtcsn	pfefpsqdmc	lsalkrieee	kpdcskarce	180
	vqfsprcped	svliegyapp	geccplpsrc	vcnpagclrk	vcqpgnlnil	vskasgkpge	240

5 ccdlyeckpv fgvdcrvec ptvqqtacpp dsyetqvrllt adgcctlptr ceclsglclgf 300  
 pvcevgstpr ivsrgdgtpg kccdvfecvn dtkpacvfnn veyydgdmmfr mdncrfrcrq 360  
 ggvaicftaq cgeinceryy vpegeccpvc edpvypfnnp agcyanglil ahgdrwredd 420  
 ctfcqcvnge rhcvatvcgq tctnpvkvpq eccpvceep t iitvdppacg elsnctltrk 480  
 dcingfkrdh ngcrtcqcqin tgclcserkq gctlncpfgf ltdaqnceic ecrprpkkr 540  
 piicdkycpl gllknkhgdc icrckkcpel scskicplgf qgdshgcllc kcreasasag 600  
 ppilsgtclt vdghhkhknee swhdgcrecy clngremcal itcpvpacgn ptihpgqccp 660  
 scaddfvvqk pelstpsich apggeyfvge etwnidsctq ctchsgrvlc etevcppllc 720  
 10 qnpsrtqdsq cpqctdqpfr pslsrnnsvp nyckndegdi flaaeswkp vctscicids 780  
 viscfesescp svscerpvlr kgqccpycik dtipkkvvch fsgkayadee rwdldscethc 840  
 yclggqtlcs tvscpplpcv epinvegsc pmcpemyvpe ptnipiekt n hrgevdlevp 900  
 lwtpsendi vhlprdmghl qvdyrdnrhl psedssldsi asvvvpiic lsiiiaflfi 960  
 nqkkqwipll cwyrtpkps slnnqlvsd ckkgtrvqv ssqrmrlrae pdarfsgfys 1020  
 15 mqkqnhlqad nfyqtv  
 <210> 35  
 <211> 716  
 <212> DNA  
 20 <213> Human  
 <400> 35  
 25 gcagtagctg gagtgctctg cagggggaaa gcgaaccggg ccctgaagtc cgggggcagtc 60  
 accgggggct cctggggccgc tctgcccggc tggggctgag cagcgatcct gctttgtccc 120  
 agaagtcacag agggatcagc cccagaacac accctcctcc cggggacgcc gcagctttct 180  
 ggaggctgag gaaggcatga agagtgggct ccacctgctg gccgactgag aaaagaattt 240  
 30 ccagaactcg gtcctatttt acagattgag aaactatggg tcaagaagag aggacggggc 300  
 ttgagggaaat ctcttgattc tccttatatg acctcaaaact gaccatacta aacagtgtag 360  
 aaggtctttt taaggctcta aatgtcaggg tctcccatcc cctgatgcct gacttggtaca 420  
 gtcagtgtgg agtagacggg ttctctccacc cagggttgac tcagggggat gatctgggtc 480  
 ccattctggg cttaagaccc caaacaaggg ttttttcagc tccaggatct ggagcctcta 540  
 35 tctgggttagt gtcgtaacct ctgtgtgcct cccgttacc catctgtcca gtgagctcag 600  
 ccccatcca cctaacaggg tgccacagg gattactgag ggtaagacc ttagaactgg 660  
 gtctagcacc cgataagagc tcaataaatg ttgttccttt ccacatcaaa aaaaaa  
 <210> 36  
 <211> 395  
 40 <212> DNA  
 <213> Human  
 <400> 36  
 45 ccaatacttc attcttcatt ggtggagaag attgtagact tctaagcatt ttccaaataa 60  
 aaaagctatg atttgatttc caacttttaa acattgcatg tccttttgcca ttactacat 120  
 tctccaaaaa aaccttgaaa tgaagaaggc cacccttaaa atacttcaga ggctgaaaaa 180  
 atgattatta cattggaatc cttagccta tgtgatattt ctttaacttt gcactttcac 240  
 gccagtaaa accaaagtca gggtaacca tgtcatttta caaatgtta aaaccctaata 300  
 50 tgcagttcct tttttaaatt attttaaaga ttacttaaca acattagaca gtgcaaaaaa 360  
 agaagcaagg aaagcattct taattctacc atcct  
 <210> 37  
 <211> 134  
 55 <212> DNA  
 <213> Human  
 <400> 37  
 60 ccctcgagcg gccgcccggg cagggtacttt taccaccgaa ttgttcactt gactttaaga 60  
 aaccataaaa gctgcctggc tttagcaaac aggcctatca acaccatggg gagtctccat 120  
 aagggaacac gtgt  
 <210> 38  
 65 <211> 644  
 <212> DNA

&lt;213&gt; Human

&lt;400&gt; 38

```

5  aagcctgttg tcatggggga ggtggtggcg cttggtggcc actggcggcc gaggtagagg 60
   cagtggcgct tgagttggtc gggggcagcg gcagatttga ggcttaagca acttcttccg 120
   gggaagagtg ccagtgagc cactgttaca attcaagatc ttgatctata tccatagatt 180
   ggaatatttg tgggccagca atcctcagac gcctcactta ggacaaatga ggaaactgag 240
   gcttggtgaa gttacgaaac ttgtccaaaa tcacacaact tgtaaaagggc acagccaaga 300
10  ttcagagcca ggctgtaaaa attaaaatga acaaattacg gcaaagtttt aggagaaaaga 360
   aggatgttta tgttccagag gccagtcgtc cacatcagtg gcagacagat gaagaaggcg 420
   ttgcgaccgg aaaatgtagc ttcccggtta agtaccttgg ccatgtagaa gttgatgaat 480
   caagaggaat gcacatctgt gaagatgctg taaaaagatt gaaagctgaa aggaagtctt 540
   tcaaaggctt ctttggaaaa actggaaaga aagcagttta agcagtttct gtgggtctaa 600
15  gcagatggac tcagagggtt tggtgaaaaa actaaggacc tcat

```

&lt;210&gt; 39

&lt;211&gt; 657

&lt;212&gt; DNA

20 &lt;213&gt; Human

&lt;400&gt; 39

```

25  ctttttgttt gggttttcca atgtagatgt ctcagtgaat tgtgcagata tactttgttc 60
   cttatatggt caccagtgtt aattatggac aaatacatta aaacaaggtt tcctggccca 120
   gcctcccacg taatctcttt gatactcttg gaatctaagt ctgaggagcg atttctgaat 180
   tagccagtgt tgtaccaact ttctgttagg aattgtatta gaataacctt tctttttcag 240
   acctgctcag tgagacatct tggggaatga agtaggaaaa tagacatttg gtggaaaaaac 300
   agcaaaatga gaacattaaa aagactcatt caagtatgag tataaagggc atggaaattc 360
30  tggtcctttg agcaaaatga gaagaaaaaa ttctgctcag cagtattcac tgtgttaaga 420
   ttttttgttt tttacacgaa tggaaaaatg atgtgtaagt ggtatagatt ttaatcagct 480
   aacagtcact ccagagattt tgatcagcac caattcctat agtagtaagt atttaaaagt 540
   taagaaatac tactacattt aacattataa agtagagttc tggacataac tgaaaattag 600
   atgtttgctt caatagaaat ttgttccac ttgtattttc aacaaaatta tcggaac

```

35

&lt;210&gt; 40

&lt;211&gt; 1328

&lt;212&gt; DNA

&lt;213&gt; Human

40

&lt;400&gt; 40

```

45  acaattttta aataactagc aattaatcac agcatatcag gaaaaagtac acagtgagtt 60
   ctggttagtt tttgtaggct cattatggtt agggctcgta agatgtatat aagaacctac 120
   ctatcatgct gtatgtatca ctcatcccat ttcatgttc catgcatact cgggcatcat 180
   gctaataatgt atccttttaa gcactctcaa ggaaacaaaa gggcctttta tttttataaa 240
   ggtaaaaaaa attcccaaaa tattttgcac tgaatgtacc aaaggtgaag ggacattaca 300
   atatgactaa cagcaactcc atcacttgag aagtataata gaaaatagct tctaaatcaa 360
   acttccctca cagtgcctg tctaccacta caaggactgt gcacttaagt aataattttt 420
50  taagattcac tatatgtgat agtatgatat gcattttatt aaaatgcatt agactctctt 480
   ccattccatca aatactttac aggatggcat ttaatacaga tatttcgtat ttccccact 540
   gctttttatt tgtacagcat cattaaacac taagctcagt taaggagcca tcagcaaac 600
   tgaagagatc agtagtaaga attccatttt cctcatcag tgaagacacc acaaattgaa 660
   actcagaact atattttctaa gcctgcattt tcaactgatgc ataattttct tagtaatatt 720
55  aagagacagt ttttctatgg catctccaaa actgcatgac atcactagtc ttacttctgc 780
   ttaatttttt gagaaggat tcttcatttt aattgctttt gggattactc cacatctttg 840
   tttatttctt gactaatcag attttcaata gagtggaagt aaattggggg tcataaaagc 900
   attggattga catatggttt gccagcctat gggtttacag gcattgccc aacatttctt 960
   tgagatctat atttataagc agccatggaa ttcttattat gggatgttgg caatcttaca 1020
60  ttttatagag gtcatatgca tagttttcat aggtgttttg taagaactga ttgctctcct 1080
   gtgagttaag ctatgtttac tactgggacc ctcaagagga ataccactta tgttacactc 1140
   ctgcactaaa ggcacgtact gcagtgtaat gaaatgttct gaaaaaggtt tatagaaatc 1200
   tggaaataag aaaggaagag ctctctgtat tctataattg gaagagaaaa aaagaaaaac 1260
   ttttaactgg aaatgttagt ttgtacttat tgatcatgaa tacaagtata tatttaattt 1320
65  tgaaaaaa

```

<210> 41  
 <211> 987  
 <212> DNA  
 <213> Human

5

<400> 41

```

aacagagact ggcacaggac ctcttcattg caggaagatg gtagttagg caggtaacat 60
tgagctcttt tcaaaaaagg agagctcttc ttcaagataa ggaagtggta gttatggtgg 120
10 taacccccgg ctatcagtcc ggatgggtgc caccctcctt gctgtaggat ggaagcagcc 180
atggagtggg agggaggcgc aataagacac cctccacag agcttggcat catgggaagc 240
tggttctacc tcttcctggc tcctttgttt aaaggcctgg ctgggagcct tccttttggg 300
tgtctttctc ttctccaacc aacagaaaag actgctcttc aaagggtggag ggtcttcatg 360
aaacacagct gccaggagcc caggcacagg gctggggggc tggaaaaagg agggcacaca 420
15 ggaggaggga ggagctggta gggagatgct ggctttacct aagggtctcga aacaaggagg 480
gcagaatagg cagaggcctc tccgtcccag gccattttt gacagatggc gggacggaaa 540
tgcaatagac cagcctgcaa gaaagacatg tgttttgatg acaggcagtg tggccgggtg 600
gaacaagcac aggccttggg atccaatgga ctgaatcaga accctaggcc tgccatctgt 660
cagccgggtg acctgggtca attttagcct ctaaaagcct cagtctcctt atctgcaaaa 720
20 tgaggcttgt gatacctgtt ttgaaggggt gctgagaaaa ttaaagataa gggatccaa 780
aatagtctac ggccatacca ccctgaacgt gcctaattct gtaagctaag cagggtcagg 840
cctggttagt acctggatgg ggagagtatg gaaaacatac ctgccgcgag ttggagtgg 900
actctgtctt aacagtagcg tggcacacag aaggcactca gtaaatactt gttgaataaa 960
tgaagtagcg atttggtgtg aaaaaaa

```

25

<210> 42  
 <211> 956  
 <212> DNA  
 <213> Human

30

<400> 42

```

cggacgggtg ggcggacgcg tgggtgcagg agcaggggcg ctgccgactg cccaaccaa 60
ggaaggagcc cctgagtcg cctgcgcctc catccatctg tccggccaga gccggcatcc 120
35 ttgcctgtct aaagccttaa ctaagactcc cgccccgggc tggccctgtg cagaccttac 180
tcaggggatg tttacctggt gctcgggaag ggaggggaag gggccgggga gggggcacgg 240
caggcgtgtg gcagccacac gcaggcgccc agggcgccca gggacccaa gcaggatgac 300
cacgcacctc cagccactg cctccccga atgcatttgg aaccaaagtc taaactgagc 360
tcgcagcccc cgcgcctcc ctccgcctcc catcccgtt agcgtctg acagatggac 420
40 gcaggccctg tccagcccc agtgcgctcg ttccggtccc cacagactgc cccagccaac 480
gagattgctg gaaaccaagt caggccaggt gggcggaaca aagggccagg tgcggcctgg 540
ggggaacgga tgctccgagg actggactgt tttttcaca catcgttgcc gcagcgttgg 600
gaaggaaagg cagatgttaa tgatgtgttg gtttacagg tatatttttg ataccttcaa 660
tgaattaatt cagatgtttt acgcaaggaa ggacttacc agtattact ctgctgtgct 720
45 tttgatctct gcttaccgtt caagaggcgt gtgcaggccg acagtcggtg acccatcac 780
tcgcaggacc aagggggcg ggactgctgg ctcacgcccc gctgtgtcct cctccccctc 840
ccttccttgg gcagaatgaa ttcgatgcgt attctgtggc cgccatctgc gcagggtgg 900
ggtattctgt catttacaca cgtcgttcta attaaaaagc gaattatact ccaaaa

```

50

<210> 43  
 <211> 536  
 <212> DNA  
 <213> Human

55

<400> 43

```

aaataaacac ttccataaca ttttgttttc gaagtctatt aatgcaatcc cacttttttc 60
cccctagttt ctaaatgtta aagagagggg aaaaaaggct caggatagtt ttcacctcac 120
60 agtgtagtct gtcttttatt ttactcttgg aaatagagac tccattaggg ttttgacatt 180
ttgggaaccc agttttacca ttgtgtcagt aaaacaataa gatagtttga gagcatatga 240
tctaaataaa gacatttgaa gggttagttt gaattctaaa agtaggtaat agccaaatag 300
cattctcatc ccttaacaga caaaaactta tttgtcaaaa gaattagaaa aggtgaaaat 360
attttttcca gatgaaactt gtgccacttc caattgacta atgaaatata agggagacaga 420
ctggaaaaag tgggttatgc cacttttaaa accctttctg gtaaataatta tggtagctaa 480
65 aggggtggtt ccccggcacc tggacctgga caggtagggt tccgtgggtt accagt

```



<210> 44  
<211> 1630  
<212> DNA  
<213> Human

5

<400> 44

10

15

20

25

30

35

40

45

50

55

60

65

ggggaggggac gagtatggaa ccctgaaggt agcaagtcca ggcactggcc tgaccatccg 60  
gctccctggg caccaagtcc caggcaggag cagctgtttt ccatcccttc ccagacaagc 120  
tctattttta tcacaatgac ctttagagag gtctcccagg ccagctcaag gtgtcccact 180  
atcccctctg gagggaaagag gcaggaaaat tctcccggg tccctgtcat gctactttct 240  
ccatcccagt tcagactgtc caggacatct tatctgcagc cataagagaa ttataaggca 300  
gtgatttccc ttaggccag gacttgggcc tccagctcat ctgttccttc tgggccatt 360  
catggcagggt tctgggtcca aagctgaact ggggagagaa gagatacaga gctaccatgt 420  
gactttacct gattgcctc agtttgggtg tgcttattgg gaaagagaga gacaaagagt 480  
tacttggttac gggaaatatg aaaagcatgg ccaggatgca tagaggagat tctagcaggg 540  
gacaggattg gctcagatga cccctgaggg ctcttcaggt cttgaaatgc attccatgat 600  
attaggaagt cgggggtggg tgggtggtgg gggctagtgt gggttgaatt taggggccga 660  
tgagcttggg tacgtgagca ggggtgttaag ttagggctct cctgtatttc tggccccctt 720  
ggaaatgtcc ccttcttcag tgtcagacct cagtcaccag gtccatatcg tgcccagaaa 780  
agtagacatt atcctgcccc atcccttccc cagtgcactc tgacctagct agtgcctggt 840  
gcccagtgac ctgggggagc ctgggtgcag gccctcactg gttccctaaa ccttggtggc 900  
tgtgattcag gtccccagg gggactcagg gaggaatatg gctgagttct gtagttcca 960  
gagttggctg gtagagcctt ctagagggtc agaattattag cttcaggatc agctgggggt 1020  
atggaattgg ctgaggatca aacgtatgta ggtgaaagga taccaggatg ttgctaaaag 1080  
tgagggacag tttgggtttg ggacttacca ggggtgatgt agatctggaa cccccaagtg 1140  
aggctggag gagttaaggt cagtatggaa gatagggttg ggacagggtg ctttggaatg 1200  
aaagagtgc cttagagggc tccttgggcc tcaggaatgc tcctgctgct gtgaagatga 1260  
gaaggtgctc ttactcagtt aatgatgagt gactatattt accaaagccc ctacctgctg 1320  
ctgggtccct tgtagcacag gagactgggg ctaagggcc ctcacaggga agggacacca 1380  
tcaggcctct ggctgaggca gtagcataga ggatccattt ctacctgcat ttcccagagg 1440  
actagcagga ggcagccttg agaaaccggc agttcccaag ccagcgctg gctgttctct 1500  
cattgtcact gccctctccc caacctctcc tctaaccac tagagattgc ctgtgtcctg 1560  
cctcttgctc cttgtagaat gcagctctgg ccctcaataa atgcttctg cattcatctg 1620  
caaaaaaaaaa

<210> 45  
<211> 169  
<212> DNA  
<213> Human

<400> 45

tcttttgctt ttagcttttt atttttgtat taacaggagt cttattacac ataggtctga 60  
taaaactggg ttatgatctt cagtctgatt ccagtgtctc ataactagat aacgtatgaa 120  
ggaaaaacga cgacgaacaa aaaagtaagt gcttgaaga cttagttga

<210> 46  
<211> 769  
<212> DNA  
<213> Human

<400> 46

tgcagggtcat atttactatc ggcaataaaa ggaagcaaag cagtattaag cagcgggtgga 60  
atttgcgcgt ttcacttttt ataaagtgtc acataaaaatg tcatatttcc aaatttataa 120  
acataactcc agttcttacc atgagaacag catgggtgatc acgaaggatc ttcttgaaaa 180  
aaacaaaaac aaaaaacaaa aacaatgatc tcttctgggt atcacatcaa atgagataga 240  
aaggtgtact aggcaatctt agagatctgg caacttattt tatatataag gcatctgtga 300  
ccaagagacg ttatgaatta aatgtacaaa tgtattatgt ataaatgtat taaatgcaag 360  
cttcatataa tgacaccaat gtctctaagt tgctcagaga tcttgactgg ctgtggccct 420  
ggccagctcc ttctctgata gtctgattct gccttcatat ataggcagct cctgcatc 480  
catgccagtg aatgagaaaa caagcatgga atatataaac tttaacatta aaaaatgttt 540  
tattttgtaa taaaatcaaa tttccatttg aaaccttcaa aaactttgca gaatgaggtt 600  
ttgatatatg tgtacaagta gtaccttctt agtgcaagaa aacatcatta tttctgtctg 660  
cctgcctttt tgttttttaa aatgaagact atcattgaaa caagtttgtc ttcagtatca 720

ggacatgttg acggagagga aaggtaggaa agggttaggg atagaagcc

<210> 47

<211> 2529

5 <212> DNA

<213> Human

<400> 47

```

10 tttagttcat agtaatgtaa aaccatttgt ttaattctaa atcaaatcac tttcacaaca 60
   gtgaaaatta gtgactgggt aaggtgtgcc actgtacata tcatcatttt ctgactgggg 120
   tcaggacctg gtcctagtc acaagggtgg caggaggagg gtggaggcta agaacacaga 180
   aaacacacaa aagaaaggaa agctgccttg gcagaaggat gaggtggtga gcttgccgag 240
   ggatgggtgg aagggggctc cctgttgggg cggagccagg agtcccaagt cagctctcct 300
15 gccttactta gctcctggca gaggtgagtg ggggacctac gaggttcaaa atcaaatggc 360
   atttgccagg cctggcttta ctaacagggt cccagagtgc ctctgttggc tgagctctcc 420
   tgggctcact ccatttcatt gaagagtcca aatgattcat tttcctaccc acaacttttc 480
   attattcttc tggaaccca tttctgttga gtccatctga cttaagtcct ctctccctcc 540
   actagttggg gccactgcac tgaggggggt cccaccaatt ctctctagag aagagacact 600
20 ccagagggccc ctgcaacttt gcggtatttc agaaggtgat aaaaagagca ctcttgagtg 660
   ggtgcccagg aatgtttaaa atctatcagg cacactataa agctgggtgt ttcttctctac 720
   caagtggatt cggcatatga accacctact caatacttta tttttgtct gtttaaacac 780
   tgaactctgg tgttgacagg tacaaggagg aagagatggg gactgtgaag aggggagggc 840
   ttccctcctc ttcctcaaga tctttgttcc cataaactat gcagtcataa ttgagaaaaa 900
25 gcaatagatg gggcttccta ccatttgttg gttattgctg gggttagcca ggagcagtg 960
   ggatggcaaa gtaggagaga ggcccagagg aaagcccatc tccctccagc tttgggggtc 1020
   ccagaaagag gctggatttc tgggatgaag cctagaaggc agagcaagaa ctgttccacc 1080
   aggtgaacag tctacctgc ttggtaccat agtccctcaa taagattcag aggaagaagc 1140
   ttatgaaact gaaaatcaaa tcaaggtatt gggaagaata atttcccctc gattccacag 1200
30 gagggagagc cacacaatat cattgtgctg gggctcccca aggccctgcc acctggcttt 1260
   acaaatcatc aggggttgcc tgcttgagc ttacatgctt ccctgggttt agcacacata 1320
   caaggagttt tcagggaact ctatcaagcc atacaaaaat cagggtcaca tgtgggtttc 1380
   ccctttcctt gcctcttcat aaaagacaac ttggcttctg aggatggtgg tcttttgcat 1440
   gcagtggggc tgacctgaca aagccccagc tttcctgttg caggttctgg gagaggatgc 1500
35 attcaagctt ctgcagccta ggggacaggg ctgcttgctc agttattact gcctcgagc 1560
   tccaaatccc accaaagtcc tgactccagg tctttcctaa tgcacagtag tcagctcag 1620
   cttcggcagt attctcggct gtatgttctc tggcagagag aggcagatga acatagttt 1680
   agggagaaag ctgatgggaa acctgtgagt taagccacat gtctcaccag gaataattta 1740
   tgccaggaaa ccaggaaagtc attcaagttg ttctctgagg ccaaagacac tgagcacagc 1800
40 ccagagccaa taaaagatct ttgagtctct ggtgaattca cgaagtgacc ccagctttag 1860
   ctactgcaat tatgattttt atgggacagc aatttcttgc atctctacag aggaagaaga 1920
   gggggagtg gaggggagag aaagagaaca gagcggcact gggatttgaa aggggaacct 1980
   ctctatctga ggagcccca ctggcttcag aagcaactta ccaaggggta tttaaagaca 2040
   tgaaaatttc cagaaatacc atttggtgca tccctttgtt tctgtaatat taaactcagg 2100
45 tgaaattata ctctgacagt ttctctcttt ctgcctcttc cctctgcaga gtcaggacct 2160
   gcagaactgg ctgaaacaag atttcatggt gtcacccatg agagatgact caatgccaa 2220
   gcctgaagtt atagagtgtt tacagcgggt gcgatattca ggggtcatcg ccaactgggt 2280
   tcgagttcca aagctctgat gaagaaacaa gactccttga tgtgttactg atccactga 2340
   ttccaggagt caagattagc caggaagcca aacaccagga gttgggggtg cacgtcacca 2400
50 gtccagagcc ctgccacgga tgtacgcagg agcccagcat taggcaatca ggagccagaa 2460
   catgatcacc agggccacaa ataggaagag gcgtgacagg aactgctcgt ccacatacct 2520
   ggggtgtcc

```

<210> 48

55 <211> 1553

<212> DNA

<213> Human

<400> 48

```

60 tttttttttt tttttgattt ctgggacaat taagctttat ttttcatata tatatatatt 60
   ttcatatata tatatacata catatataaa ggaaacaatt tgcaaattha cacacctgac 120
   aaaaccatat atacacacat atgtatgcat acacacagac agacacacac acccgaagct 180
   ctagccaggc ccgttttcca tccctaagta ccattctctc atttggggcc ttctaggggt 240
65 ggggccctga gcttggtttg tagaagtttg gtgctaatat aaccatagct ttaatcccca 300
   tgaaggacag tgtagacctc atctttgtct gctccccgct gcctttcagt tttacgtgat 360

```

5 ccatcaagag ggctatggga gccaaagtga caccgggggat tgaggctaata tcacctgaac 420  
 tcgaaaacag cggccagctt cctcaccgca ggcacgcgtc ttttcttttt ttttctcga 480  
 gacggagtct cgctgtgttg cccaggctgg agtgagtg caccgtctcg gctcactgca 540  
 agctccacct cctggattca taccattctc ctgcttcagc cttccgagta gctgggacta 600  
 taggtgccaa ccactacgcc tagctaattt tttttgtat ttttagtaga gacagggttt 660  
 caccgtgtta gccaggatgg tctcgtcctg actttgtgat ccgccgcct cggcctccca 720  
 aagtgtctggg attacaggcg tgagccacca cactggccc cggcacgtat cttttaagga 780  
 atgacaccag ttcctggctt ctgaccaaag aaaaaatgtc acaggagact ttgaagaggc 840  
 10 agacaggagg gtggtggcag caacactgca gctgcttctg gatgctgctg ggggtgctctc 900  
 cggagcgggt gtgaacagcg cacttcaaca tgagcaggcg cctggctccg gtgtgtcctc 960  
 acttcagtgg tgcacctgga tgggtggaagc cagcctttgg ggcaggaac cagctcagag 1020  
 aggctaccca gctcagctgc tggcaggagc caggatttta cagccataat gtgtgtaaag 1080  
 aaaaaacacg ttctgcaaga aactctccta cccgctcggg agactggggc tccttgcttg 1140  
 ggatgagctt cactcaacgt ggagatggtg gtggactggt ccctgaaaag cgggccttg 1200  
 15 agggccaagt gaggtcctca ggtcctaac ccagtggccc tctgaaaggg ggtgtgcagg 1260  
 cgaggggagc aggaggctt tctctagtcc ctttggaggc tttggctgag agaagagtga 1320  
 gcaggggagct gggaatggtc caggcaggga agggagctga agtgattcgg ggctaattgc 1380  
 tcagatcgat gtatttctct ccctggtctc ccggagccct cttgtcaccg ctgctgcct 1440  
 20 gcaggaggcc catctcttct gggagcttat ctgacttaac ttcaactaca agttcgtct 1500  
 tacgagaccg ggggtagcgt gatctcctgc ttccctgagc gcctgcacgg cag

&lt;210&gt; 49

&lt;211&gt; 921

&lt;212&gt; DNA

25 &lt;213&gt; Human

&lt;400&gt; 49

30 ctgtggtccc agctactcag gaggtgagg cgggaggatt gcttgagccc aggagttgga 60  
 tggtgcagtg agccaagatc gcaccattgc cctccactct gggccacgga gcaataccct 120  
 gtctcagaaa acaaaaca aaaaagcagaa acgctgaagg ggtcggttta cgggaaaacc 180  
 gcctgtcaga acacttggt actcctaccc cagatcagtg gacctgggaa tgagggttg 240  
 tccccggagg cttttctcca agctgttgcc accagacccg ccatgggaac cctggccaca 300  
 35 gaagcctccc ggggagtgag ccagagcctg gaccgctgtg ctgatgtgtc tggggtggag 360  
 ggagggtggg gagtgtgcaa ggggtgtgtg gtgcccgggg ggtgttcattg ggcaagcatg 420  
 tgcgtgctcg tgtgtgtgctg tgcctctccc ctgcagccgt cgggtgtatc tccctccagc 480  
 cccttcgcca ccttctgagc attgtctgtc cagtgagac tgcccagaga cagcagagct 540  
 ccacgtggtt ttaaggggag acctttccct ggacctgggg gtctcgccgt atctcatgac 600  
 cagggtgctaa atgacccgac atgcacacc tgcttttoga tgaccaacct ccctgtcccc 660  
 40 gtcccgtgta cctgcccccg tggcgtctca cgggtgatgcc tgctcctgac attgggtgtc 720  
 actgtagcaa actacattct ggatgggaat tttcatgtac atgtgtggca tgtggaaaat 780  
 ttcaaataaa attgacttga tttagaaagc caaaaagctg tgtggtcctt ccagcacgga 840  
 tactttgacc tcttgcttac aaccccttcc ttgggtccga ggctggtagc tttgttccact 900  
 45 tcagatggtt gggggcgggt g

&lt;210&gt; 50

&lt;211&gt; 338

&lt;212&gt; DNA

50 &lt;213&gt; Human

&lt;400&gt; 50

55 atgatctatc tagatgcctt accgtaaaat caaaacacaa aaccctactg actcattccc 60  
 tcccttccag atattacccc atttctctac ttcccattgt agccaaactt tccaaaaatt 120  
 catgttctgt cttcatttcc tcatgttcaa cccaccctgt cttagctacc acccctcagt 180  
 aacgacctag cctgggtaga acaaatgtc agcatgatac catactcaat gatccttcgt 240  
 cactgttgctc attgtcatca ttccatggcc ttactttccc tctcagcgcc atttgctaca 300  
 gtaagaaact ttctttcttg aattcttggg tctcttgg

60 &lt;210&gt; 51

&lt;211&gt; 1191

&lt;212&gt; DNA

&lt;213&gt; Human

65 &lt;400&gt; 51

23

5 ctagcaagca ggtaaacgag ctttgtacaa acacacacag accaacacat ccggggatgg 60  
 ctgtgtgttg ctagagcaga ggctgattaa aactcagtg tgttggctct ctgtgccact 120  
 cctggaaaat aatgaattgg gtaaggaaca gtaataaga aaatgtgcct tgctaactgt 180  
 gcacattaca acaaagagct ggcagctcct gaaggaaaag ggcttgtgcc gctgccgttc 240  
 aaacttgtca gtcaactcat gccagcagcc tcagcgtctg cctccccage acaccctcat 300  
 tacatgtgtc tgtctggcct gatctgtgca tctgtcggga gacgtcctg acaagtcggg 360  
 aatttctcta tttctccact ggtgcaaaga gcggatttct ccctgcttct cttctgtcac 420  
 ccccgctcct ctccccagg aggtccttg atttatggta gctttggact tgcttccccg 480  
 10 tctgactgtc cttgacttct agaatggaag aagctgagct ggtgaaggga agactccagg 540  
 ccatcacaga taaaagaaaa atacaggaag aaatctcaca gaagcgtctg aaaatagagg 600  
 aagacaaact aaagcaccag catttgaaga aaaaggcctt gagggagaaa tggcttctag 660  
 atggaatcag cagcggaaaa gaacaggaag agatgaagaa gcaaaatcaa caagaccagc 720  
 accagatcca ggttctagaa caaagtatcc tcaggcttga gaaagagatc caagatcttg 780  
 aaaaagctga actgcaaate tcaacgaagg aagaggccat tttaaagaaa ctaaagtcaa 840  
 15 ttgagcggac aacagaagac attataagat ctgtgaaagt ggaaagagaa gaaagagcag 900  
 aagagtcaat tgaggacatc tatgtctaata tccctgacct tccaaagtcc tacatacctt 960  
 ctaggttaag gaaggagata aatgaagaaa aagaagatga tgaacaaat aggaaagctt 1020  
 tatatgccat ggaaattaaa gttgaaaaag acttgaagac tggagaaagt acagttctgt 1080  
 cttccaatac ctctggccat cagatgactt taaaagggtac aggagtaaaa gtttaagatg 1140  
 20 atgggcacaaa gtccagtgtg ttcagtaaaag tgctaatacac aagttggagg t

&lt;210&gt; 52

&lt;211&gt; 1200

&lt;212&gt; DNA

25 &lt;213&gt; Human

&lt;400&gt; 52

30 aacagggact ctactctat caaccccagg ctggagtcgg gtgcgcccac cctggctccc 60  
 tgcaacctcc gcctcccagg ctcaagcaac tctcctgcct cagtcgctct agtagctggg 120  
 actacaggca cacaccacca tgcccagcca atttttgcat tttttgtaga gacagggttt 180  
 cgccttctgt ccaggccggc atcatatact ttaaatcatg ccagatgac tttaatacct 240  
 aatacaatat atcaggttgg tttaaaaata attgcttttt tattattttt gcattttttg 300  
 35 accaacctta atgctatgta aatagttggt atactgttgc ttaacaacag tatgacaatt 360  
 ttggcttttt ctttgtatta ttttgtattt ttttttttta ttgtgtgggc tttttttttt 420  
 ttctcagtggt tttcaattcc tccttgggtg aatccatgga tgcaaaaccc acagatatga 480  
 agggctggct atatatgcat tgatgattgt cctattatat tagttataaa gtgtcattta 540  
 atatgtatgt aaagttatgg tacagtggaa agagtgttg aaaacataaa catttggacc 600  
 40 tttcaagaaa ggtagcttgg tgaagttttt caccttcaaa ctatgtccca gtcagggtc 660  
 tgctactaat tagctataat ctttgcacaa attacatcac ctttgagtct cagttgcctc 720  
 acctgtaaaa tgaaagaact ggatactctc taaggctcact tccagccctg tcattctata 780  
 actctgttat gctgaggaag aaattcacat tgtgttaact gtatgagtca aactgaaat 840  
 gattattaaa gtgggaaaaa gccaatgtct tctcttagaa agctcaacta aatttgagaa 900  
 45 gaataatctt ttcaattttt taagaatttt aatattttta agggtttgac ctattttatt 960  
 agagatgggg tctcactctg tcacccagac tggagtacag tggcacaatc atagctcact 1020  
 gctgcctcaa attcatgggc tcaagtgtac ctctgcctc tgccctcaga gtagctgcga 1080  
 ctatgggcat gtgccaccac gcttggttaa ctttgtattt gacctattta tttattgtga 1140  
 tttatatctt tttttttttt tctttttttt ttttttacia aatcagaaat acttattttg 1200

50 &lt;210&gt; 53

&lt;211&gt; 989

&lt;212&gt; DNA

&lt;213&gt; Human

55 &lt;400&gt; 53

60 aagccaccac tcaaaacttc ctatacattt tcacagcaga gacaagtga catttatttt 60  
 tatgcctttc ttcctatgtg tatttcaagt ctttttcaaa acaaggcccc aggactctcc 120  
 gattcaatta gtccttgggc tggctgactg tgcaggagtc caggagacct ctacaaatgc 180  
 agagtgactc tttaccaaca taaaccctag atacatgcaa aaagcaggac ccttcctcca 240  
 ggaatgtgcc atttcagatg cacagcaccg atgcagaaaa gctggaattt tccttggaa 300  
 cgactgtgat agaggtgctt acatgaacat cgtactgtc tttctttttt tttgagacag 360  
 gtttctgttg tgcccaggct gagtgcacat cgtgatctca ctactgcaa ttccacctcc 420  
 aggttcaagc atttctcctg tcagcctcct agtagctggg ttacaggcac tgccaccatg 480  
 65 ccggctaatt ttgtattttt gtagagatgg atttctccat ttggctcagg ggtctcgaac 540  
 cccaacctca gtgatctgcc acctcagcct cctaagtgtt ggattacagg atgagccacc 600

	cgaccggcca	ctactgtctt	tctttgaccc	ttccagtttc	gaagataaag	aggaaataat	660
	ttctctgaag	tacttgataa	aattttccaaa	caaaacacat	gtccacttca	ctgataaaaa	720
	atttaccgca	gttttgccacc	taagagtatg	acaacagcaa	taaaaagtaa	tttcaaagag	780
5	ttaagatttc	ttcagcaaaa	tagatgattc	acatcttcaa	gtcctttttg	aaatcagtta	840
	ttaatatatt	tctttcctca	tttccatctg	aatgactgca	gcaatagttt	tttttttttt	900
	tttttttttt	ttgcgagatg	gaatctcgct	ctgtcgccca	gcgggagtg	actggcgcaa	960
	gcccggctca	ccgcaatctc	tgccacccg				
	<210>	54					
10	<211>	250					
	<212>	DNA					
	<213>	Human					
	<400>	54					
15	catttcccca	ttggtcctga	tggtgaagat	ttagttaaag	aggctgtaag	tcaggttcga	60
	gcagaggcta	ctacaagaag	tagggaatca	agtccctcac	atgggctatt	aaaactaggt	120
	agtgggtggag	tagtgaaaaa	gaaatctgag	caacttcata	acgtaactgc	ctttcaggga	180
20	aaagggcatt	cttttaggaac	tgcatctggg	aaccacacac	ttgatccaag	agctagggaa	240
	acttcagttg						
	<210>	55					
	<211>	2270					
25	<212>	DNA					
	<213>	Human					
	<400>	55					
30	gcgccccga	gcagcgcccg	cgccctccgc	gccttctccg	ccgggacctc	gagcgaaaga	60
	ggccccgcgc	ccgcccagcc	ctcgccctcc	tgcccaccgc	gcacaccgcg	ccgccacccc	120
	gaccccgctg	cgcacggcct	gtccgctgca	caccagcttg	ttggcgctct	cgctcgccgc	180
	ctcgccccgg	gctaactctg	cgcgccacaa	tgagctcccg	catcgccagg	gcgctcgcc	240
	tagtcgtcac	ccttctccac	ttgaccaggc	tgggcgctct	cacctgcccc	gctgcctgcc	300
	actgccccct	ggaggcgccc	aagtgcgcgc	cgggagtcgg	gctggctccg	gacggctgcg	360
35	gctgctgtaa	ggtctgcgcc	aagcagctca	acgaggactg	cagcaaaacg	cagccctgcg	420
	accacacca	ggggctggaa	tgcaacttcg	gcgccaaagtc	caccgctctg	aaggggatct	480
	gcagagctca	gtcagagggc	agaccctgtg	aatataactc	cagaatctac	caaaacgggg	540
	aaagtttcca	gcccactgt	aaacatcagt	gcacatgtat	tgatggcgcc	gtgggctgca	600
40	ttcctctgtg	tcccaagaa	ctatctctcc	ccaacttggg	ctgtcccaac	cctcggtcgg	660
	tcaaagttac	cgggcagtg	tgcgaggagt	gggtctgtga	cgaggatagt	atcaaggacc	720
	ccatggagga	ccaggacggc	ctccttgcca	aggagctggg	attcgatgcc	tccgaggtgg	780
	agttgacgag	aaacaatgaa	ttgattgcag	ttggaaaagg	cagctcactg	aagcggtccc	840
	ctgttttttg	aatggagcct	cgcatcctat	acaacccttt	acaaggccag	aaatgtattg	900
	ttcaaacaac	ttcatgggtc	cagtgtcaa	agacctgtgg	aactgggtatc	tccacacgag	960
45	ttaccaatga	caaccctgag	tgccgccttg	tgaagaaac	ccggatttgt	gaggtgcggc	1020
	cttgtggaca	ccagtgtagc	agcagcctga	aaaagggcaa	gaaatgcagc	aagaccaaga	1080
	aatccccga	accagtcagg	tttacttacg	ctggatgttt	gagtggtgaag	aaataccggc	1140
	ccaagtactg	cggttcctgc	gtggacggcc	gatgctgcac	gccccagctg	accaggactg	1200
	tgaagatgcg	gttccgctgc	gaagatgggg	agacattttc	caagaacgtc	atgatgatcc	1260
50	agtcctgcaa	atgcaactac	aactgcccgc	atgccaatga	agcagcgttt	cccttctaca	1320
	ggctgttcaa	tgacattcac	aaatttaggg	actaaatgct	acctgggttt	ccaggggcaca	1380
	cctagacaaa	caaggagaa	gagtgctcaga	atcagaatca	tgagagaaat	ggcggggggt	1440
	ggtgtgggtg	atgggactca	ttgtagaaag	gaagccttgc	tcattcttga	ggagcattaa	1500
	ggtattttcg	aactgccaag	ggtgctggtg	cggtatggaca	ctaattgcagc	cacgatttga	1560
55	gaatactttg	cttcatagta	ttggagcaca	tgttactgct	tcatttttga	gcttgtggag	1620
	ttgatgactt	tctgttttct	gtttgttaaa	tatttgctaa	gcataattttc	tctaggtttt	1680
	tttccttttg	gggttctaca	gtcgtaaaag	agataataag	attagtttga	cagttttaaag	1740
	cttttattcg	tcctttgaca	aaagtaaatg	ggagggcatt	ccatcccttc	ctgaaggggg	1800
	acactccatg	agtgtctgtg	agaggcagct	atctgcactc	taaactgcaa	acagaaatca	1860
60	ggtgttttaa	gactgaatgt	tttattttatc	aaaatgtagc	ttttggggag	ggaggggaaa	1920
	tgtaaatctg	gaataatttg	taaatgattt	taattttata	ttcagtgaag	agatttttatt	1980
	tatgggaata	accattttaa	aaagaaatat	ttaccttaata	tctgagtgtg	tgccattcgg	2040
	tatttttaga	ggtgctccaa	agtcattagg	aacaacctag	ctcacgtact	caattattca	2100
	aacaggactt	attgggatac	agcagtgaat	taagctatta	aaataagata	atgattgctt	2160
65	ttataccttc	agtagagaaa	agtcttttga	tataaagtaa	tgtttaaaaa	acatgtattg	2220
	aacacgacat	tgtatgaagc	acaataaaga	ttctgaagct	aaaaaaaaaa		

10	cttgaatgaa agcgctcgag cagtttgatt tggtttgctt cagttcatcc cggggcagcc agccccgtgc gatgtctctt gtgcagacag agcttcacac atctgggacc gtttactgct tcggctcttc agcagtggtg gataccaatg acccaggttg tgcttctctc tgggcccttg acattttttc tggaacagctc ttcctaacaa acatacaag cctgtcaaag tttctttggg tttttgctt aagacaattt aagatgggtg gacctgtgc	gctgacacca ttggaaagga ggaagtccag ggtctcaagg ctaaagggtt caaaagagaa cttccccacc gcttggttct ggctcctgct ccagtggcag tgaataaaca gtttactctc tatggagcat tctcttgtga tgattatgtg accccgcat cagaaggctt aactgaaaac cacatgggtg ctagggtcct cttaccaggt ctttttaagc ggagttgctg attgtgaata taaatagata gatacataat agagtgggat tgctt	agaaccgcgg accgctgctg ctgtgaaacc acactgcac tgaaggcaaa gacgtgtgac cagcaggaag tgctacggga tttgaatctt tttgatttgg cggtaaacag cccagactgc gaggtcctac cttctcccc ggaccctcat ggatgacagt gtaccttgcc tcccattgca agtcattgcc gtcctcactg cctagcactg aacaccacat gaataatggg gaatgtagca caaatgtcta aaaaaattat ggatgaggag	gaagagcttg ctggccgaac tggaagcgctg gtcaaactga agccgaagta tgtgtgtcaga ctctgggcac ctcaacgatg tccggccacc gtctccgcgt atccaagtgt agctatgtgt acgttaattc gactctgccc accggcgaaa gacgtccaca acggtggcag tttgctccta acagggacaa aagcacttat ccaatcccca cttgctcttc ccaacacatc aaaccagatt tcaactttaa gacaatgtcc cgtggtgacg	ggcccaaagc tcaagcccgg ccttctcccc tcccctggcc gcaaaaatga tgtcttggg gccaccaccc ggcagatcaa aacgatgtcgt cacgggataa tatcgggcca ctctgtcagc ggaagctaga tgcttgtcac ggctgaggtc ttagctcact atgacagact tgaccaatgg gagatggcca gccggaagc agaaaaatga ttgtagcag ggctctgcat ccagtgata tcaaagaatt tcaagtgta tgggaaaaaa gggcctgca	aggaagggga gcgccccac agatggctcc gttggaggag gacgaaaggg ctcggccttc ccaagtgcc gatctgggag gagatctctg gactcttcgc cctgcagtgg tggagaaga gggccatcaa ggcttcttac actccaccac gagatctgtg cctcaggatc gctttgctgc cgtccagttc ccttcgaagt agattctctc ggtaaatcgt tgaaatagca taaaagaatt acttatattg aaaatgtaga gcggggtggg	60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380 1440 1500 1560 1620
----	--	--	--	--	---	---	---

<210> 57  
<211> 460  
<212> DNA  
<213> Human

45	ccatgtgtgt	atgagagaga	gagagattgg	gagggagagg	gagctcacta	gcgcatatgt	60
	gcctccaggg	ggctgcagat	gtgtctgagg	gtgagcctgg	tgaaagagaa	gacaaaagaa	120
	tggaatgagc	taaagcagcc	gcctgggggtg	ggaggccgag	cccatttgta	tgagcagggt	180
	ggcaggagcc	cagcaaggga	gcctccattc	ccaggactct	ggagggagct	gagaccatcc	240
	atgcccgcag	agccctccct	cacactccat	cctgtccagc	cctaattgtg	caggtgggga	300
50	aactgaggct	gggaagtca	atagcaagtg	actggcagag	ctgggactgg	aaccaacca	360
	gcctctctaga	ccacggttct	tcccatcaat	ggaatgtctag	agactccagc	caggtgggta	420
	ccgagctcga	attcgttaatc	atggtcatag	ctgtttcctg			

<210>	58
<211>	1049
<212>	DNA
<213>	Human

60	atctgatcaa	gaataacctgc	cctggctact	ctgcggatgt	ttctgtccac	ttgttcacat	60
	tgaggaccaa	gatatccttt	tttacagagg	cacttgttcg	gtctaacaca	gacacctcca	120
	tgacgacatg	ctggctcaca	ttttgcagtt	ctgcagaagt	ccccctcca	gcctggacta	180
	cagcagcact	ttcccgtggg	gggtgcagtag	ccgttttcgac	agagcctgga	gcactctgaa	240
65	gtcagtgctc	gtgcaggttg	taccctggct	ctgcattcct	caggcattaa	aggtcttttg	300
	gqatctacaa	ttttgtaaag	ttttccattg	tgaagtctggg	ctataactttt	actgcttgat	360

5   aaaatgtaaa cttcacctag ttcattcttct ccaaattccca agatgtgacc ggaaaagtag 420  
      cctctacagg acccactagt gccgacacag agtgggtttt cttgccactg ctttgtcaca 480  
      ggacttttct ggagagttag gaaattccca ttacgatctc caaacacgta gcttccatac 540  
      aatcttttctg actggcagcc ccggtataca aatccacca ccaaaggacc attactgaat 600  
      ggcttgaatt ctaaaagtga tggctcactt tcataatctt tcccctttat tatctgtaga 660  
      attctggctg atgatctgtt ttttccattg gagtctgaac acagtatcgt taaattgatg 720  
      tttatatcag tgggatgtct atccacagca catctgcctg gatcgtggag cccatgagca 780  
      aacacttcgg ggggctgggt ggtgctgttg aagtgtgggt tgctccttgg tatggaataa 840  
 10   ggcacgttgc acatgtctgt gtccacatcc agcgttagca ctgagcctgt gaaatcactt 900  
      aaccatcca tttcttccat atcatccagt gtaatcatcc catcaccaag aatgatgtac 960  
      aaaaaccgt cagggccaaa gagcagttgc cctccagat gctttctgtg gagttctgca 1020  
      acttcaagaa agactctggc tgttctcaa

15   <210> 59  
      <211> 747  
      <212> DNA  
      <213> Human

20   <400> 59

25   tttttcaaat cacatatggc ttctttgacc ccatcaaata actttattca caaaaacgtc 60  
      ccttaattta caaagcctca gtcattcata cacattaggg gatccacagt gttcaaggaa 120  
      cttaaataata atgtatcata ccaacccaag taaaccaagt aaaaaaata ttcataataa 180  
      gttggttcaca cgtaggctct agattaccag cttctgtgca aaaaaaggaa atgaagaaaa 240  
      atagatttat taactagtat tggaaactaa ctttgtgcct ggcttaaaac ctccctcacg 300  
      ctcgtctgtc ccacacaaat gtttaagaag tcaactgcaat gtactccccg gctctgatga 360  
      aaagaagccc ctggcacaaa agattccagt gcccctgaag aggctccctt cctcctgtgg 420  
      gctctcctag aaaaccagcg ggacggcctc cctgctgata ccgtctataa ccttaggggg 480  
      ccctcgggca ggcaacggca gtggactcat ctcggtgatg gctgtagatg ctaacactgg 540  
 30   ccaattcaat gccacaccta ctggttacc tttgagggca tttctccaga cagaagcccc 600  
      ttgaagccta ggtagggcag gatcagagat acaccgtgt ttgtctcgaa gggctccaca 660  
      gcccagtagc acatgcttgc agaagtagta tctctggact tctgcctcca gtcgaccggc 720  
      cgcgaaattta gtagtaatag cggccgc

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☐ FADED TEXT OR DRAWING

☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**